

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12803 A2

(51) International Patent Classification⁷: C12N 15/11

(21) International Application Number: PCT/US00/22086

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/149,313 17 August 1999 (17.08.1999) US

(71) Applicant (for all designated States except US): **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.**
[US/US]: 1 Deaconess Road, Boston, MA 02215 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **INOUE, Roger, T.** [US/US]: 23 Roberts Road, Wellesley, MA 02481 (US). **TORRES-VIERA, Carlos** [VE/VE]: Calle Andrea de Ledesma, Qta La Torrerá, Urb Sorocaima, Caracas,

Venezuela (VE). **MOELLERING, Robert** [US/US]: 49 Longfellow Road, Wellesley Hills, MA 02481-5220 (US). **GOLD, Howard** [US/US]: Apartment 610, 135 Pleasant Street, Brookline, MA 02446-3489 (US). **ELIOPOULOS, George, M.** [US/US]: 5 Laurel Circle, Needham, MA 02494 (US).

(74) Agent: **PLUMER, Elizabeth, R.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:


— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviation" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/12803 A2

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*



(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a *vanR*-responsive promoter decoy.

-1-

**METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC
SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS***

Related Applications

5 This application claims priority under 35 USC §119(e) from U.S. Provisional Patent Application Serial No. 60/149,313, filed on August 17, 1999, entitled METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*. The contents of the provisional application are hereby expressly incorporated by reference.

Government Support

10 This work was funded in part by the National Institutes for Allergy and Infectious Diseases/National Institutes of Health under Grant KO8 AI01518. The government may retain certain rights in this invention.

Field of the Invention

15 This invention relates to methods for reducing antibiotic resistance in vancomycin resistant bacteria.

Background of the Invention

20 Over the past decade, the emergence of antibiotic-resistant bacteria, particularly multidrug-resistant strains, have created an increasingly concerning clinical dilemma (Gold, et al., *N. Engl. J. Med.*, 1996, 335:1445-1453). Included among these pathogens are enterococci which have developed relative, and in some cases, absolute resistance to the
25 mainstays of antimicrobial therapy, including beta-lactam and aminoglycoside antibiotics, and more recently, the glycopeptide, vancomycin (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65). While new pharmacologic agents continue to be developed in order to remedy this therapeutic shortfall, drug resistance and consequential treatment failure to even investigational agents such as the streptogramins in the setting of vancomycin-resistant
30 enterococcal infections highlight the ongoing need for effective, potentially novel means of treating these organisms (Chang, et al., *Diag. Microbiol. Infect. Dis.*, 1999;33:299-303).

-2-

Vancomycin Resistant Enterococcus

Enterococci are Gram-positive cocci which, prior to DNA homology studies, were classified as Lancefield group D streptococci (Moellering, R.C. Jr., In: Mandell GL, Bennett JE and Dolin R eds. *Principles and Practices of Infectious Diseases*. New York:Churchill Livingstone. 1995:1826-1835). While these organisms are known constituents of the gastrointestinal and genital tract bacterial flora, enterococci have rapidly emerged as clinically relevant pathogens especially in the nosocomial setting. In fact, enterococci are the second most common cause of nosocomial infections in the United States as well as a frequent cause of nosocomial bacteremia (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65); Schaberg, et al., *Am. J. Med.*, 1991;91(3B):72S-85S). Far from being inconsequential, the mortality attributable to vancomycin resistant enterococcal bacteremia has been estimated to approach 25% in some studies (Edmond, et al., *Clin. Infect. Dis.*, 1996;23:1234-1239).

Vancomycin Mechanism-of-Action

First introduced in the 1950's as a means for treating penicillin-resistant staphylococcal infections, vancomycin, a glycopolypeptide antibiotic, has become the drug-of-choice for the treatment of beta-lactam antibiotic-resistant Gram-positive bacterial infections (Fekety, et al., In: Mandell, et al. *Principles and Practices of Infectious Diseases*. New York:Churchill Livingstone, 1995;346-354). While other ancillary mechanisms-of-action continue to be investigated, the major mechanism of vancomycin is the inhibition of polymerization and transpeptidation of the bacterial cell wall peptidoglycan (Ge, et al., *Science* 1999;284:507-11). This structure serves an important function in bacteria: the inhibition of osmolysis. In the wildtype enterococci, cell wall production is characterized by peptidoglycan synthesis in which two D-alanines are ligated to form a dipeptide which is then added to the carboxy-terminus of peptidoglycan precursors (Walsh, C.T., *J. Biol. Chem.*, 1989;264:2393-2396). Vancomycin interferes with this process by complexing with the terminal D-alanine residues at the outer portion of the cytoplasmic membrane (Beauregard, et al., *Antimicrob. Agents chemother.*, 1995;39:791-785; Reynolds, et al., *Euro. J. Clin. Microbiol. Infect. Dis.*, 1989;9:43-950). This blocks subsequent cell wall formation by perturbing the further processing of peptidoglycan precursors by transglycosidases. Vancomycin also blocks catalysis by enterococcal transpeptidases and D,D-carboxypeptidases.

Vancomycin Resistance

-3-

Several phenotypes of glycopeptide resistance in enterococci have been described (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65). Class A glycopeptide resistance (VanA), which was targeted in this study, is found in both the clinically relevant *Enterococcus faecalis* and *Enterococcus faecium* species, and is characterized by high-level
5 vancomycin resistance with MICs ≥ 64 $\mu\text{g/mL}$ as well as resistance to teicoplanin, a related glycopeptide antibiotic (Eliopoulos, G.M., *Infect. Dis. Clin. North. Am.* 1997;11:851-65).

The genotypic characterization of Class A vancomycin resistance has uncovered potential targets for gene-based anti-drug resistance determinant strategy. The genetic basis for VanA phenotypic resistance is a transposon-based operon consisting of 7 genes including
10 *vanR*, *vanS*, *vanH*, *vanA*, *vanX*, *vanY*, and *vanZ* (Arthur, et al., *Antimicrob. agent Chemother.*, 1993;37:1563-1571; Bugg, et al., *Biochem.*, 1991;30:2017-2021) (Figure 1). The products of these genes function in concert to negate the inhibitory effects of vancomycin by, in essence, allowing for an alternate biosynthetic pathway for the production of cell wall precursors which less avidly bind vancomycin. The transcription of *vanH*, *-A*, and *-X* are under the
15 control of the *vanH* promoter. This promoter is inducible by the binding of the phosphorylated gene product of *vanR* (Arthur, et al., *J. Bacteriol.*, 1992;174:2582-2591; Holman, et al., *Biochem.*, 1994;33:4625-4631).

Therapeutic Gene Transfer Background

In an attempt to inhibit pathogens which are refractory to conventional
20 pharmacological antimicrobial agents, gene-based therapeutics have been studied, though for the most part, in eukaryotic systems. For example, nucleic acid binding decoys, antisense nucleic acids (antisense RNA and DNA), ribozymes, and trans-dominant mutants are among the many gene therapy motifs which have been used to target the expression of key viral functions in human immunodeficiency virus, type 1; human papilloma virus; hepatitis viruses, and Herpesviridae infections (Chatterjee, et al., *Science*, 1992, 258:1485-1488; Weiss, et al.,
25 *Cell. Mol. Life. Sci.*, 1999, 55:334-58; Yamada, et al., *Virol.*, 1996, 70:1596-1601; Inouye, et al., *J. Virol.*, 1997, 71(5):4071-4080; Yamamoto, et al., *Hepatology*, 1999, 30:300-307; Shillitoe, et al., *Cancer Gene Ther.*, 1994, 1:193-204; Flores-Aguilar, et al., *J. Infect. Dis.*, 1997, 175:1308-1316). Additionally, they have been studied for their ability to inhibit pro-
30 oncogenic cellular functions (Mercola, et al., *Cancer Gene Ther.*, 1995, 2:47-59; Seth, et al., *Cancer Gene Ther.*, 1997, 4:383-390; Rubin, et al., *Curr. Opin. Pediatr.*, 1999, 11:39-46).

A cornerstone of a successful gene-based tactic is that the target nucleic acid sequence encode for pivotal, highly conserved pathogenic functions. In eukaryotic viral and oncologic

-4-

systems, antisense nucleic acids, for example, have also been specifically used to inhibit the expression of key viral or cellular functional proteins including the expression of drug resistance determinants (Gao, et al., *Anticancer Res.*, 1998, 18:3073-3076; Inouye, et al., *Antiviral Therapy*, 1999, 4 (Supplement 1):121). In comparison, examples of gene-based strategies in prokaryotic systems are scant (Takada-Guerrier, et al., *Proc. Natl. Acad. Sci USA*, 1997;94:8468-8472; White, et al., *Antimicrob. Agent Chem.*, 1997, 41:2699-2704; Rom, et al., *Am. J. Res. Crit. Care. Med.*, 1997, 156:1993-1998; Nielson, et al., *Nat. Biotech.*, 1998, 16:355-358), and in particular, with enterococci or more specifically, with vancomycin-resistant enterococci, have yet to be reported. Although data have been published on the use of anti-resistance determinant genetic elements in other microorganisms (e.g. *Escherichia coli* and *Staphylococcus aureus*) there are yet no published data on the use of this technology for vancomycin-resistant *Enterococcus* (Takada-Guerrier, et al., *Proc. Natl. Acad. Sci USA*, 1997, 94:8468-8472; White, et al., *Antimicrob. Agent Chem.*, 1997, 41:2699-2704).

Summary of the Invention

In the most basic of terms, a successful strategy against antibiotic resistant enterococci would require either (1) the retention of antimicrobial activity despite the presence of the drug resistance mechanism (i.e. a lack of cross-resistance), or (2) the perturbation of the antibiotic resistance mechanism itself and, as a consequence, reversion of the bacterium to a drug-susceptible phenotype. In our studies, the unique approach taken towards the treatment of vancomycin-resistant enterococci is of the latter type. Herein, we present a gene-based strategy which targets a key vancomycin resistance determinant and results in the restoration of vancomycin susceptibility in previously glycopeptide-resistant enterococci.

Thus, the invention overcomes the above-noted and other problems of the prior art by providing methods and related compositions for reducing antibiotic resistance in vancomycin resistant microorganisms. More particularly, the present invention provides a gene cassette comprised of the *vanH* promoter and a single copy of a *vanA* antisense gene in an enterococcal shuttle vector. Using this invention, we have demonstrated an ability to increase the vancomycin susceptibility in previously resistant *Enterococcus faecalis*.

According to one aspect of the invention, a method for reducing vancomycin resistance in a vancomycin-resistant organism is provided. The method involves introducing into the organism at least one "anti-sense vancomycin resistance molecule" under conditions to inhibit expression of a vancomycin resistance gene. By "inhibit expression" it is meant to

-5-

inhibit replication, transcription, and/or translation of a vancomycin gene since inhibition of any of these processes results in the inhibition of expression of a protein encoded by a vancomycin gene. Exemplary vancomycin-resistant organisms include the Gram-positive bacteria *Enterococcus faecium* and *Enterococcus faecalis* and other bacteria to which these organisms have the potential of transferring resistance determinants, given that VanA is a transferable form of resistance and that it could be transferred to other clinically significant pathogens such as *Streptococcus Pneumococcus*, and *Staphylococcus*. (See, e.g., Brisson-Noel A., et al., *J. Bacteriol*, 1988, 170:1739-1745).

Preferably, the vancomycin resistant organism is a Gram-positive bacteria and, more preferably, the organism is an *Enterococcus*.

Vancomycin resistance can take a variety of forms depending upon the nature of the gene cluster which mediates the resistance phenotype. Thus, exemplary vancomycin resistant organisms of the invention may exhibit one or more of the following phenotypes: VanA resistance, VanB resistance, VanC resistance, and VanD resistance. VanA resistance is mediated by a gene cluster which includes seven genes: *vanR* (SEQ ID NO:18), *vanS* (SEQ ID NO:19), *vanH* (SEQ ID NO:20), *vanA* (SEQ ID NO:21), *vanX* (SEQ ID NO:22), *vanY* (SEQ ID NO:23), and *vanZ* (SEQ ID NO:24).

In a preferred embodiment in which the vancomycin resistant organism carries a VanA genotype, the antisense vancomycin resistance molecule is selected from the group consisting of antisense molecules which hybridize under stringent conditions to these target genes or to conserved regions of these target genes (e.g., SEQ ID NOS: 5, 6, 7, 8, 9, and 10). As used herein, such antisense molecules to these target genes are referred to as *vanR* antisense molecules, *vanS* anti-sense molecules, *vanH* anti-sense molecules, *vanA* anti-sense molecules, *vanX* anti-sense molecules, *vanY* anti-sense molecules, and *vanZ* anti-sense molecules, respectively. In a particularly preferred embodiment, the organism is a VanA type, and the anti-sense vancomycin resistance molecule hybridizes under stringent conditions to the *vanA* target gene (SEQ ID NO:21), or to a conserved region of the *vanA* gene (e.g., SEQ ID NOS: 7, and 8). In a further preferred embodiment, the organism is a VanA type, and the anti-sense vancomycin resistance molecule hybridizes under stringent conditions to the *vanX* target gene (SEQ ID NO:22), or to a conserved region of the *vanX* gene (e.g., SEQ ID NO:10).

Additionally or alternatively, the vancomycin resistant organism can be a VanB, VanC, and/or VanD type organism and the anti-sense vancomycin resistance molecule is a

-6-

nucleic acid molecule which hybridizes under stringent conditions to these target genes (SEQ ID NO:2 is the vanB gene cluster sequence; SEQ ID NO:3 is the vanC gene sequence; SEQ ID NO:4 is the vanD gene cluster sequence) or to conserved regions of these target genes (e.g., SEQ ID NOS: 11, 12, and 13).

5 In general, the antisense molecules which hybridize to a conserved region of a target vancomycin resistance gene contain from about 18 to about 1500 nucleotides, more preferably from about 10 to about 30 nucleotides, and most preferably from about 20 to about 30 nucleotides.

In general, the anti-sense vancomycin resistance molecules are introduced to the
10 organism by contacting the vancomycin resistant organism with at least one cassette (typically contained in a vector) comprising one or more "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes. In general, the vector comprises an expression cassette which permits expression of the anti-sense vancomycin resistance molecules in the
15 organism. The preferred vectors are selected from the group consisting of: an enterococcal shuttle vector (e.g., see the Examples), an enterococcal bacteriophage (Merril CR, et al., *Proc Natl Acad Sci USA*, 1996, 93:3188-92); the nucleic acid portion of a peptide nucleic acid molecule (Good L, et al., *Nat Biotechnol*, 1998; 16:355-8); an enterococcal conjugative transposon or pheromone-responsive plasmid (Murray BE, *Emerg Infect Dis*, 1998, 4:37-47).

20 In certain embodiments such as those described in detail in the Examples, the cassette contains one or more copies of a *vanA* antisense molecule operatively coupled to a promoter, preferably, the same inducible promoter which drives expression of the *vanH*, *vanA*, and *vanX* resistance determinant, e.g., a *VanR*-responsive promoter such as the *vanH* promoter. As used herein, a *VanR*-responsive refers to a promoter which activates transcription in
25 response to binding of a phosphorylated *VanR* protein.

Preferably, the *VanR*-responsive promoter is a *vanH* promoter (P_{vanH}) or a *vanR* promoter (P_{vanR}), each of which directs transcription of the genes of the vancomycin resistance operon found in several species. These *VanR*-responsive promoters activate transcription in response to binding of an activated *VanR* protein. These promoters include,
30 in addition to the *VanR* binding sites, all other sequences required for efficient transcriptional activation of the gene or genes located downstream of the promoters. In general, these *VanR*-responsive promoters (P_{vanH} , P_{vanR}) include the 60 nucleotides immediately upstream (nucleotides -60 to -1) of the genes encoding a *VanR* protein or a *VanR* protein, which

-7-

sequences include a *VanR* binding site, and other sites which contribute to efficient *VanR*-responsive activation of gene transcription.

Other *VanR*-responsive promoters can be used to effect transcription of protein coding sequences. For example, alternative *VanR*-responsive promoters can be identified by
5 searching databases of bacterial nucleotide sequences for sequences which have *VanR* binding sites in proximity to sites which contribute to efficient bacterial transcriptional activation, e.g. a consensus binding site for bacterial DNA polymerase. Such sites are well-known to one of ordinary skill in the art. *VanR*-responsive promoters can also be identified by genetic screening and cloning protocols that are standard in the art, as described in Sambrook.
10 Further, non-natural *VanR* promoters can be prepared by combining a *VanR* binding site with the other nucleotide sequences which contribute to efficient bacterial transcriptional activity. Such synthetic or non-natural *VanR*-responsive promoters can be synthesized directly by chemical means, such as by use of an automated DNA synthesizer.

In an analogous manner, other embodiments can be prepared in which the expression
15 cassette contains one or more copies of a different vancomycin resistance antisense molecule operatively coupled to a promoter which drives expression of the targeted antisense gene.

In yet another aspect of the invention, an alternative method for reducing vancomycin resistance is provided. According to this aspect of the invention, the method involves enhancing expression of a *VanR*-responsive promoter, such as a *vanH* promoter, in the
20 organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism. As used herein, a "vancomycin resistance gene of the organism" refers to the gene in its native configuration contained within the genome of the organism, i.e., not isolated from the organism.

25 In certain preferred embodiments, the *vanH* promoter is operatively coupled to an antisense vancomycin resistance molecule, such as a *vanA* anti-sense molecule. More preferably, the *vanH* promoter (alone or operatively coupled to an antisense vancomycin resistance molecule) is contained in a cassette. Typically, the cassette is contained in a vector to facilitate transport into and out of the resistant organism. In a particularly preferred
30 embodiment, the vector is an *enterococcal* vector and enhancing expression of the *vanH* promoter involves introducing the vector into the organism. Although not wishing to be bound to a particular theory or mechanism, it is believed that introducing the vector into the

-8-

organism results in expression of an amount of the *vanH* promoter sufficient that is sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism.

In further preferred embodiments, the *VanR*-responsive promoter, such as a *vanH* promoter is co-administered into the organism together with an antisense vancomycin resistance molecule
5 operatively coupled to a *vanH* promoter.

According to still other aspects of the invention, compositions for use in accordance with the methods of the invention are provided. In certain embodiments, the compositions of the invention are isolated nucleic acids that hybridize under stringent conditions to a targeted vancomycin gene or a conserved region thereof, such as described in more detail below. In a
10 particularly preferred embodiment, the isolated nucleic acid is vancomycin resistance gene sequence which has been cloned in the opposite direction (see, e.g., the Examples). Exemplary target genes and conserved regions thereof include the genes which are contained in the VanA resistance gene cluster (GenBank Accession No. M97297, SEQ ID NO:1), the VanB resistance gene cluster (GenBank Accession No. U35369, SEQ ID NO:2), the VanC
15 resistance gene cluster (GenBank Accession No. L29638, SEQ ID NO:3), and the VanD resistance gene cluster (GenBank Accession No. AF130997, SEQ ID NO:4). The location of the individual genes in each gene cluster is set forth in each GenBank listing. Thus, the anti-sense molecules of the invention have sequences which are complementary, and therefore capable of hybridizing to the target genes identified herein, as well as to conserved and/or
20 unique regions of these genes (e.g., by using routine skill to search nucleic acid databases such as GenBank to identify regions of the vancomycin resistance genes which are conserved and/or which are unique). In certain preferred embodiments, the anti-sense molecules of the invention hybridize to regions of the target gene which encode an active site or other which encodes an active site or other functional portion of the encoded protein (e.g., the active site
25 of the ligase encoded by the *vanA* gene). Using such techniques, Applicants have identified the following nucleotide regions of representative target genes to which the anti-sense molecules can be designed to hybridize (i.e., the anti-sense molecules have complementary nucleotide sequences to the target genes or the selected regions).

SUMMARY TABLE

30	<u>SEQ ID</u> <u>NO</u>	<u>GENE/ACC</u> <u>NO</u>	<u>NUCLEOTIDE</u> <u>NOS</u>	<u>TARGETED SEQ</u> <u>NO</u>
	5	<i>vanS</i> /M97297	5657 to 5684	5'-ggtggcgcgggacttggatggcgattg-3'
	6	<i>vanR</i> /M97297	4258 to 4287	5'ggcgcggatgattatataacgaagccctt-3'

-9-

7	<i>vanA</i> /M97297	7719 to 7736	5'-cgagccggaaaaaggctc-3'
8	<i>vanA</i> /M97297	7339 to 7358	5'-ggctgcgatattcaaagctc-3'
9	<i>vanH</i> /M97297	6033 to 6059	5'-attactgtttatggatgtgagcaggat-3'
10	<i>vanX</i> /M97297	8343 to 8368	5'-gtggcttcaaaatcaagccatagccg-3'
5 11	<i>VanB</i> /U35369	5708 to 5725	5'-cgagccggaaaaaggctc-3'
12	<i>VanB</i> /U35369	5328 to 5347	5'-ggctgcgatattcaaagctc-3'
13	<i>VanD</i> /AF130997	4443 to 4462	5'-ggctgcgatattcaaagctc-3'

It will be understood that anti-sense molecules which contain a few nucleotide residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) which hybridize to either side of the above-identified conserved nucleotide regions are embraced within the meaning of the anti-sense molecules disclosed and claimed herein for use in accordance with the methods of the invention.

According to still other aspects of the invention, cassettes containing the isolated nucleic acids of the invention, as well as vectors containing such nucleic acids and/or cassettes, also are provided. Preferably the cassettes further comprise a vancomycin-inducible promoter (e.g., a *VanR*-responsive promoter such as a *vanH* promoter) operatively coupled to one or more isolated nucleic acid molecules of the invention. In still other embodiments, isolated vancomycin resistant organisms containing any of the foregoing isolated nucleic acids, cassettes and/or vectors also are provided.

These and other embodiments and utilities of the invention will become more apparent in reference to the following drawings and detailed description of the preferred embodiments.

All references are incorporated in their entirety herein by reference.

Brief Description of the Sequences

SEQ ID NO:1 -- The nucleic acid encoding the VanA resistance gene cluster of *Enterococcus faecium*. GenBank accession number M97297.

SEQ ID NO:2 -- The nucleic acid encoding the VanB resistance gene cluster of *Enterococcus faecalis*. GenBank accession number U35369.

SEQ ID NO:3 -- The nucleic acid encoding the VanC resistance gene cluster of *Enterococcus casseliflavus*. GenBank accession number L29638.

SEQ ID NO:4 -- The nucleic acid encoding the VanD resistance gene cluster of *Enterococcus faecium*. GenBank accession number AF130997.

SEQ ID NO:5 -- A conserved nucleic acid region of the *vanS* gene of the VanA gene cluster.

-10-

SEQ ID NO:6 -- A conserved nucleic acid region of the *vanR* gene of the VanA gene cluster.

SEQ ID NO:7 -- A conserved nucleic acid region of the *vanA* gene of the VanA gene cluster (nucleotides 7719 to 7736).

5 SEQ ID NO:8 -- A conserved nucleic acid region of the *vanA* gene of the VanA gene cluster (nucleotides 7339 to 7358).

SEQ ID NO:9 -- A conserved nucleic acid region of the *vanH* gene of the VanA gene cluster.

10 SEQ ID NO:10 -- A conserved nucleic acid region of the *vanX* gene of the VanA gene cluster.

SEQ ID NO:11 -- A conserved nucleic acid region of the *vanB* gene cluster (nucleotides 5708 to 5725).

SEQ ID NO:12 -- A conserved nucleic acid region of the *vanB* gene cluster (nucleotides 5328 to 5347).

15 SEQ ID NO:13 -- A conserved nucleic acid region of the *vanD* gene cluster.

SEQ ID NO:14 -- A 5' -PCR primer oligonucleotide sequence for the *vanH* promoter, used in conjunction with the primer of SEQ ID NO:15.

SEQ ID NO:15 -- A 3' -PCR primer oligonucleotide sequence for the *vanH* promoter, used in conjunction with the primer of SEQ ID NO:14.

20 SEQ ID NO:16 -- A 5' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:17.

SEQ ID NO:17 -- A 3' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:16.

25 SEQ ID NO:18 -- The nucleotide sequence of the *vanR* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:19 -- The nucleotide sequence of the *vanS* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:20 -- The nucleotide sequence of the *vanH* gene of the VanA gene cluster (SEQ ID NO:1).

30 SEQ ID NO:21 -- The nucleotide sequence of the *vanA* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:22 -- The nucleotide sequence of the *vanX* gene of the VanA gene cluster (SEQ ID NO:1).

-11-

SEQ ID NO:23 -- The nucleotide sequence of the *vanY* gene of the VanA gene cluster (SEQ ID NO:1).

SEQ ID NO:24 -- The nucleotide sequence of the *vanZ* gene of the VanA gene cluster (SEQ ID NO:1).

5 SEQ ID NO:25 -- A 3' -PCR primer oligonucleotide sequence for the *vanA* gene, used in conjunction with the primer of SEQ ID NO:16.

SEQ ID NO:26 -- The nucleotide sequence of the *vanRB* gene of the VanB gene cluster (SEQ ID NO:2).

10 SEQ ID NO:27 -- The nucleotide sequence of the *vanSB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:28 -- The nucleotide sequence of the *vanYB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:29 -- The nucleotide sequence of the *vanHB* gene of the VanB gene cluster (SEQ ID NO:2).

15 SEQ ID NO:30 -- The nucleotide sequence of the *vanB* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:31 -- The nucleotide sequence of the *vanXB* gene of the VanB gene cluster (SEQ ID NO:2).

20 SEQ ID NO:32 -- The nucleotide sequence of the *vanW* gene of the VanB gene cluster (SEQ ID NO:2).

SEQ ID NO:33 -- The nucleotide sequence of the *vanC-2* gene of the VanC gene cluster (SEQ ID NO:3).

SEQ ID NO:34 -- The nucleotide sequence of the *vanRD* gene of the VanD gene cluster (SEQ ID NO:4).

25 SEQ ID NO:35 -- The nucleotide sequence of the *vanSD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:36 -- The nucleotide sequence of the *vanYD* gene of the VanD gene cluster (SEQ ID NO:4).

30 SEQ ID NO:37 -- The nucleotide sequence of the *vanHD* gene of the VanD gene cluster (SEQ ID NO:4).

SEQ ID NO:38 -- The nucleotide sequence of the *vanD* gene of the VanD gene cluster (SEQ ID NO:4).

-12-

SEQ ID NO:39 -- The nucleotide sequence of the *vanXD* gene of the VanD gene cluster (SEQ ID NO:4).

Brief Description of the Drawings

5 **Figure 1.** A schematic showing the organization of genes in the VanA vancomycin resistance operon.

Figure 2. Schematic maps of the shuttle vectors and relevant cloning sites; Fig. 2A shows the parent vector, pAM401; Fig. 2B shows the restriction sites for the *vanH* promoter insertion into pAM401; Fig. 2C shows the restriction sites for the *vanA* antisense insertion
10 into *vanH* promoter/pAM401 construct.

Figure 3. A schematic showing the proposed nucleic acid binding decoy mechanism with the introduction of a shuttle vector carrying the *vanH* promoter alone.

Figure 4. A schematic of the proposed mechanism-of-action of the pAM401-*vanH* promoter-*vanA* antisense recombinant shuttle vector.

15

Detailed Description of the Invention

While vancomycin has been the mainstay of treatment for beta-lactam antibiotic-resistant enterococci, the increasing prevalence of vancomycin-resistant enterococci has prompted a continued search for new therapeutic approaches. In eukaryotic and prokaryotic
20 systems, gene transfer has been used to define molecular pathogenesis as well as applied towards therapeutic ends. The elucidation of the genetic basis for vancomycin resistance has uncovered potential targets for a unique anti-drug resistance gene-based strategy. Particularly, the preferred embodiments of the present invention consist of a gene cassette comprised of the enterococcal *vanH* promoter and a single copy of a *vanA* antisense gene in the shuttle
25 vector, pAM401. Using this invention, we have demonstrated the ability to increase the vancomycin susceptibility of a vancomycin-resistant *Enterococcus faecalis* by up to 32-fold.

 According to one aspect of the invention, a method for reducing vancomycin resistance in a vancomycin-resistant organism is provided. The method involves introducing into the organism at least one "anti-sense vancomycin resistance molecule" under conditions
30 to inhibit expression of a vancomycin resistance gene.

 As used herein, "reducing vancomycin resistance" refers to enhancing the susceptibility of a vancomycin resistant organism to vancomycin to a statistically significant extent. In the embodiments illustrated in the Examples, the methods of the invention have

-13-

been used to increase the vancomycin susceptibility of a vancomycin-resistant *Enterococcus faecalis* by at least about 16-fold and up to about 32-fold compared to organisms which have not been so treated. These results demonstrate the utility of the invention for reducing vancomycin resistance in the particular organisms tested, as well as the feasibility of using the methods of the invention for treating other types of glycopeptide-resistant bacteria (e.g., VanB, VanC, and VanD type bacteria).

According to certain aspects of the invention, the methods involve inhibiting expression of a vancomycin resistance gene. As used herein, "inhibit expression" refers to inhibiting (i.e., reducing to a detectable extent) replication, transcription, and/or translation of a vancomycin gene since inhibition of any of these processes results in the inhibition of expression of a protein encoded by a vancomycin gene. Exemplary vancomycin-resistant organisms include the Gram-positive bacteria *Enterococcus faecium* and *Enterococcus faecalis* and other bacteria to which these organisms have the potential of transferring resistance determinants, given that VanA is a transferable form of resistance and that it could be transferred to other clinically significant pathogens such as *Streptococcus* species, *Pneumococcus*, and *Staphylococcus* species. (See, e.g., Brisson-Noel A. Arthur, M. Courvalin P., "Evidence for natural gene transfer from Gram-positive cocci to *Escherichia coli*," *J. Bacteriol* 170:1739-1745, 1988).

Preferably, the vancomycin resistant organism is a Gram-positive bacteria and, more preferably, the organism is an *Enterococcus*.

Vancomycin resistance can take a variety of forms depending upon the nature of the gene(s) which mediates the resistance phenotype. Thus, exemplary vancomycin resistant organisms of the invention may exhibit one or more of the following phenotypes: VanA resistance, VanB resistance, VanC resistance, and VanD resistance.

VanA resistance is mediated by a gene cluster (SEQ ID NO:1) which includes seven genes: *vanR* (SEQ ID NO:18), *vanS* (SEQ ID NO:19), *vanH* (SEQ ID NO:20), *vanA* (SEQ ID NO:21), *vanX* (SEQ ID NO:22), *vanY* (SEQ ID NO:23), and *vanZ* (SEQ ID NO:24), as described in GenBank Accession No. M97297 (SEQ ID NO:1). VanB resistance is mediated by a gene cluster which includes seven genes: *vanRB* (SEQ ID NO:26), *vanSB* (SEQ ID NO:27), *vanYB* (SEQ ID NO:28), *vanHB* (SEQ ID NO:29), *vanB* (SEQ ID NO:30), *vanXB* (SEQ ID NO:31), and *vanW* (SEQ ID NO:32), as described in GenBank Accession No. U35369 (SEQ ID NO:2); VanC resistance is mediated by a *vanC-2* gene (SEQ ID NO:33), as described in GenBank Accession No. L29638 (SEQ ID NO:3); VanD resistance is mediated

-14-

by a gene cluster which includes at least six genes: *vanRD* (SEQ ID NO:34), *vanSD* (SEQ ID NO:35), *vanYD* (SEQ ID NO:36), *vanHD* (SEQ ID NO:37), *vanD* (SEQ ID NO:38), and *vanXD* (SEQ ID NO:39), as described in GenBank Accession No. AF130997 (SEQ ID NO:4). Although the Examples illustrate the application of the invention for treating *vanA* resistance, it is to be understood that the invention can be tailored to treating one or more types of antibiotic resistance to a vancomycin antibiotic by selecting antisense molecules and/or appropriate promoters which can be used to reduce expression of the resistance genes in the targeted organism.

In a preferred embodiment in which the vancomycin resistant organism is a VanA organism, the antisense vancomycin resistance molecule is selected from the group consisting of antisense molecules which hybridize under stringent conditions to these target genes or to conserved, unique, or functionally important regions of these target genes as described above. As used herein, such antisense molecules to these target genes are referred to as *vanA* antisense molecules, *vanR* antisense molecules, *vanS* anti-sense molecules, *vanH* anti-sense molecules, *vanX* anti-sense molecules, *vanY* anti-sense molecules, and *vanZ* anti-sense molecules, respectively. In a particularly preferred embodiment, the organism carries a VanA phenotype and the anti-sense vancomycin resistance molecule hybridizes under physiological conditions to the *vanA* target gene or to a conserved region of the *vanA* gene.

Additionally or alternatively, the vancomycin-resistant organism can be a VanB, VanC, and/or VanD resistant organism and the anti-sense vancomycin resistance molecule is selected which hybridizes under stringent conditions to these target genes (SEQ ID NO:2 is the VanB gene cluster sequence; SEQ ID NO:3 is the VanC gene sequence; SEQ ID NO:4 is the VanD gene cluster sequence) or to conserved regions of these target genes. In general, the antisense molecules are isolated molecules which hybridize to a conserved region of a target vancomycin resistance gene contain from about 18 to about 1500 nucleotides, more preferably from about 10 to about 30 nucleotides, and most preferably, from about 20 to about 30 nucleotides.

The nucleic acid molecules described herein preferably are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which

-15-

5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to a messenger RNA (mRNA) transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under the physiological conditions of the target organism, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding the vancomycin resistance proteins, or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides. (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases.

-16-

Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 1994, 14(5):439-457) and at which proteins are not expected to bind. Finally, although the listed sequences may include cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a vancomycin resistance gene. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding vancomycin resistance proteins. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

Exemplary U.S. patents which describe and claim antisense molecules for reducing gene expression include U.S. Patent Nos. 5,734,039; 5,783,683; 5,859,229; 5,858,987; 5,919,677; and 5,916,807; the entire contents of which patents are incorporated in their entirety herein by reference.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its oligonucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage rather than a phosphodiester linkage between the 5' end of one oligonucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not

-17-

normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

5 The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-
10 alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding vancomycin resistance polypeptides, together with acceptable carriers to deliver these molecules into the
15 target organism.

 The compositions of the invention may be administered as part of a pharmaceutical composition to a mammal (e.g., humans, domestic animals, such as dogs, cats, livestock, such as horses, sheep, cows, pigs) hosting a vancomycin resistant organism. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with
20 any standard physiologically and/or pharmaceutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological
25 system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.

 The compositions of the invention also may be introduced into vancomycin resistant
30 organisms which is *ex vivo*, i.e., not contained within a mammal. For example, the applications of such compositions include both treatment of vancomycin-resistant enterococci or other clinically significant pathogen infections and colonization including, for example: (1) *ex vivo* eradication of vancomycin-resistant enterococci from frequently colonized settings

-18-

(e.g., intensive care units, hemodialysis units, chronic care facilities); (2) *in vivo* clearance of vancomycin-resistant enterococci from colonized gastrointestinal or genitourinary tracts of human and animal subjects; and (3) primary or adjuvant therapy for vancomycin-resistant enterococcal infections. In certain embodiments, antisense oligonucleotides (e.g., a synthetic antisense DNA strand) are used as a means for delivering this motif into bacteria by delivering the genes which code for antisense RNA (e.g., by conjugation, transformation, or transduction with bacteriophage). Accordingly, the antisense motif and other anti-resistance determinant genetic elements of the invention (e.g., nucleic acid binding decoys, transdominant mutants, suicide genes, ribozymes etc.) may be introduced into enterococci via transconjugation or via recombinant bacteriophage.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host organism. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome or host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., β -galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and

-19-

expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a vancomycin polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host bacterium.

-20-

The vancomycin resistance operons of a targeted organism include, e.g., the naturally occurring operon of *Enterococcus faecium*, or such operons which are substantially identical thereto, e.g., homologs of the vancomycin resistance operon of *Enterococcus faecium* from other species, functionally equivalent variant of the vancomycin resistance operon containing
5 variants of the genes which constitute the naturally occurring operon. Such variants may be sequence variants, e.g., containing conservative substitutions of amino acids and the like as defined herein, or may be different genes which have the same or a similar function as one of the genes found in the naturally-occurring vancomycin operon. For example, the *ddlB* gene of *E. coli* encodes a protein that exhibits similar properties of the VanA protein as discussed
10 below. Thus, a preferred vancomycin resistance operon of a targeted organism typically includes a *vanH* gene, a *ddlB* gene and a *vanX* gene.

The VanA protein product has two activities: a D-Ala-D-hydroxybutyrate depsipeptide ligase activity (Bugg et al., *Biochemistry* 30:2017-2021, 1991). VanA shares 28% amino acid identity with an *E. coli* enzyme, DdlB, which is a D-Ala-D-Ala dipeptide ligase. Two point
15 mutants of DdlB recently have been reported that exhibit depsipeptide ligase activity (S150A and Y126F; Shi & Walsh, *Biochemistry* 34:2768-2776, 1995; Park et al., *Biochemistry*, 1996, *in press*). Thus, these mutants appear to be functional homologs of VanA. Other functional homologs include, for example, genes encoding a VanA or DdlB protein that are present in other vancomycin operons, including such genes present in other species which encode
20 vancomycin resistance. For example, other vancomycin resistant strains of bacteria (i.e., not *Enterococci* which have a VanA operon) have modified Ddl proteins which serve to make depsipeptide termini directly. Non-VanA vancomycin resistance operons such as the VanB vancomycin resistance operon, contain functionally equivalent VanA homologs. Other functional homologs, either natural or non-natural, are also embraced by the invention.

25 In general, the anti-sense vancomycin resistance molecules are introduced to the organism by contacting the vancomycin resistant organism with at least one cassette, preferably contained in a vector, which cassette comprises one or more "anti-sense vancomycin resistance molecules" operably coupled to a promoter (e.g., a *VanR* response promoter). The cassette is contacted with the organism under conditions which allow the
30 cassette and/or vector to enter the organism and inhibit expression of one or more vancomycin resistance genes. Typically, the vector comprises an expression cassette which permits expression of the anti-sense vancomycin resistance molecules in the organism. The preferred vectors are selected from the group consisting of: an enterococcal shuttle vector

(e.g., see the Examples), an enterococcal bacteriophage (Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S, "Long-Circulating Bacteriophage as Antibacterial Agents," *Proc Natl Acad Sci USA*, 1996; 93:3188-92); the nucleic acid portion of a peptide nucleic acid molecule (Good L, Nielsen PE, "Antisense Inhibition of Gene Expression in Bacteria by PNA Targeting To mRNA," *Nat Biotechnol* 1998; 16:355-8); an enterococcal conjugative transposon or pheromone-responsive plasmid (Murray BE, "Diversity Among Multidrug-Resistant Enterococci," *Emerg Infect Dis* 1998; 4:37-47).

In certain embodiments such as those described in detail in the Examples, the cassette contains one or more copies of a *vanA* antisense molecule, e.g., in tandem, operatively coupled to a promoter, preferably, the same inducible promoter which drives expression of the *vanA* resistance determinant, e.g., a *VanR*-responsive promoter such as the *vanH* promoter. As used herein, a *VanR*-responsive refers to a promoter which activates transcription in response to binding of an activated *VanR* protein. These promoters include, in addition to the *VanR* binding site, all other sequences required for efficient transcriptional activation of the gene or genes located downstream of the promoters. In an analogous manner, other embodiments can be prepared in which the expression cassette contains one or more copies of a different vancomycin antisense molecule operatively coupled to a promoter which drives expression of the targeted antisense gene.

In yet another aspect of the invention, an alternative method for reducing vancomycin resistance is provided. According to this aspect of the invention, the method involves enhancing expression of a *VanR*-responsive promoter (e.g., a *vanH* promoter) in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism. As used herein, a "vancomycin resistance gene of the organism" refers to the gene in its native configuration contained within the genome of the organism, i.e., not isolated from the organism or attached to nucleic acid which is not contained within the genome of the organism.

In certain preferred embodiments, the *VanR*-responsive promoter is operatively coupled to an antisense vancomycin resistance molecule, such as a *vanA* anti-sense molecule. More preferably, the *VanR*-responsive promoter (alone or operatively coupled to an antisense vancomycin resistance molecule) is contained in a cassette. Typically, the cassette is contained in a vector to facilitate transport into and out of the resistant organism. In a particularly preferred embodiment, the vector is an *enterococcal* vector and enhancing

-22-

expression of the *VanR*-responsive promoter involves introducing the vector into the organism. An exemplary cassette, vector and process for introducing the cassette into a vancomycin resistant organism and representative experimental evidence showing the efficacy of the claimed methods for reducing antibiotic resistance in a vancomycin resistant organism are described in the Examples.

Although not wishing to be bound to a particular theory or mechanism, it is believed that introducing the vector into the organism results in expression of an amount of the *VanR*-responsive promoter (e.g., a *vanH* promoter) that is sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism by competitively sequestering the phosphorylated *VanR* protein.

According to still other aspects of the invention, compositions for use in accordance with the methods of the invention are provided. In certain embodiments, the compositions of the invention are isolated nucleic acids that hybridize under stringent conditions to a targeted vancomycin gene or a conserved region thereof, such as described in more detail below. In a particularly preferred embodiment, the isolated nucleic acid is vancomycin resistance gene sequence which has been cloned in the opposite direction (see, e.g., the Examples). Exemplary target genes and conserved regions thereof include the genes which are contained in the *vanA* resistance gene cluster (GenBank Accession No. M97297, SEQ ID NO:1), the *vanB* resistance gene cluster (GenBank Accession No. U35369, SEQ ID NO:2), the *vanC* resistance gene (GenBank Accession No. L29638, SEQ ID NO:3), and the *vanD* resistance gene cluster (GenBank Accession No. AF130997, SEQ ID NO:4). The location of the individual genes in each gene cluster is set forth in each GenBank listing. Thus, the anti-sense molecules of the invention have sequences which are complementary, and therefore capable of hybridizing to the target genes identified herein, as well as to conserved and/or unique regions of these genes (e.g., by using routine skill to search nucleic acid databases such as GenBank to identify regions of the vancomycin resistance genes which are conserved and/or which are unique). In certain preferred embodiments, the anti-sense molecules of the invention hybridize to regions of the target gene which encode an active site or other which encodes an active site or other functional portion of the encoded protein (e.g., the active site of the ligase encoded by the *vanA* gene). Using such techniques, Applicants have identified the following nucleotide regions of representative target genes to which the anti-sense molecules can be designed to hybridize (i.e., the anti-sense molecules have complementary nucleotide sequences to the target genes or the selected regions).

-23-

SUMMARY TABLE

	<u>SEQ ID</u> <u>NO</u>	<u>GENE/ACC</u> <u>NO</u>	<u>NUCLEOTIDE</u> <u>NOS</u>	<u>TARGETED SEQ</u> <u>NO</u>
5	5	<i>vanS</i> /M97297	5657 to 5684	5'-ggtggcgcgggacttggatggcgattg-3'
	6	<i>vanR</i> /M97297	4258 to 4287	5'ggcgcggatgattatataacgaagcccttt-3'
	7	<i>vanA</i> /M97297	7719 to 7736	5'-cgagccggaaaaaggctc-3'
	8	<i>vanA</i> /M97297	7339 to 7358	5'-ggctgcgatattcaaagctc-3'
	9	<i>vanH</i> /M97297	6033 to 6059	5'-attactgtttatggatgtgagcaggat-3'
10	10	<i>vanX</i> /M97297	8343 to 8368	5'-gtggcttcaaatcaagccatagccg-3'
	11	<i>vanB</i> /U35369	5708 to 5725	5'-cgagccggaaaaaggctc-3'
	12	<i>vanB</i> /U35369	5328 to 5347	5'-ggctgcgatattcaaagctc-3'
	13	<i>vanD</i> /AF130997	4443 to 4462	5'-ggctgcgatattcaaagctc-3'

15 It will be understood that anti-sense molecules which contain a few nucleotide residues (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) which hybridize to either side of the above-identified conserved nucleotide regions are embraced within the meaning of the anti-sense molecules disclosed and claimed herein for use in accordance with the methods of the invention.

The term "stringent conditions" as used herein refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refers to hybridization at 20 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄ (pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at 25 65°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be 30 able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of nucleic acids encoding proteins of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

-24-

According to still other aspects of the invention, cassettes containing the isolated nucleic acids of the invention, as well as vectors containing such nucleic acids and/or cassettes, also are provided. Preferably the cassettes further comprise a vancomycin-inducible promoter (e.g., a *VanR*-responsive promoter such as a *vanH* promoter) operatively
5 coupled to one or more isolated nucleic acid molecules of the invention. In still other embodiments, isolated vancomycin resistant organisms containing any of the foregoing isolated nucleic acids, cassettes and/or vectors also are provided.

“Co-administering,” as used herein, refers to administering simultaneously two or more compounds (constructs) of the invention (e.g., the *VanR*-responsive promoter, such as a
10 *vanH* promoter, and an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter), as an admixture in a single composition, or sequentially, close enough in time so that the compounds may exert an additive or even synergistic effect, i.e., on reducing vancomycin resistance.

The invention will be more fully understood by reference to the following examples.
15 These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

Examples

Plasmids

20 The parent shuttle plasmid used in the test vector constructs was pAM401 (American Type Culture Collection, Rockville, MD) (Wirth, et al., *J. Bacteriol.*, 1986;165:831-836). This plasmid is a high copy shuttle vector containing both Gram-negative bacillary (*Eschericia coli*) and enterococcal (*Enterococcus faecalis*) elements necessary for replication in these two bacterial types (Figure 2). To aid in selection of appropriately transformed
25 clones, this plasmid also contains tetracycline and chloramphenicol resistance genes.

The cloning vector, pAMP1 (Gibco BRL, Rockville, MD), was also employed for the cloning of polymerase chain reaction-amplified fragments.

Construction of Recombinant Enterococcal Shuttle Vectors

The structures of the recombinant pAM401 shuttle vectors, including their pertinent
30 restriction sites and vector constituents, are outlined in Figure 2 (Wirth, et al., *J Bacteriol*, 1986, 165:831-6). To construct a pAM401 shuttle vector containing the *vanH* promoter alone, *vanHP* was removed from pAMP1-*vanHP* using Xba I and Sal I restriction enzymes and ligated into pAM401 pre-digested with the same enzymes with the resultant pAM401-*vanHP*

-25-

shuttle vector (Figure 2). To produce the pAM401-*vanHP-vanA* antisense, *vanA* was digested out of pAMP1-*vanA* antisense with Xho I and Sal I and cloned into the Sal I site in pAM401-*vanHP* in the anti-coding direction.

Bacterial Strains

5 Vancomycin-resistant *Enterococcus faecalis* strains, designated A407 and A403, were VanA phenotype clinical isolates obtained from E. Cercenada (Hospital General Gregorio Marañón, Madrid, Spain). A1221 is a VanA strain of *Enterococcus faecium* resulting from the transconjugation with a VanA strain of *Enterococcus faecalis* (A312) obtained from F. Tenover (Centers for Disease Control, Atlanta, GA). These strains were identified as
10 *Enterococcus faecalis* or *faecium* by the use of API-Rapid Strep Strips (bioMeriux Vitex, Inc., Hazelwood, MO). The presence of the *vanA* genotype was confirmed by DNA probe analysis as previously described (Eliopoulos, et al., *Antimicrob. Agents Chemother.*, 1998, 42:1088-92).

Vancomycin susceptibilities were determined by the National Committee for Clinical
15 Laboratory Standards agar dilution method (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A4. Wayne, PA: NCCCLS, 1997). Commercially prepared competent DH5-alpha *Eschericia coli* (Gibco BRL, Rockville, MD) were also used in the cloning and sub-cloning of the vectors via a standard transformation protocol
20 (Sambrook, et al., In: *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 1989; 1.74).

Antibiotics, Culture Media, Cloning Reagents

Vancomycin and other antimicrobial agents were purchased from Sigma (St. Louis, MO). Restriction and modifying enzymes were obtained from Promega (Madison, WI) and
25 New England BioLabs, Inc. (Beverly, MA). *Eschericia coli* were grown in Luria-Bertani medium and enterococci were grown on Mueller-Hinton or Blood-agar medium. Plasmid preparations were performed using Promega Wizard DNA Purification systems (Madison, WI).

vanH Promoter and vanA Antisense Construction

30 An approximate 450 base-pair fragment containing the *vanH* promoter - previously described to be necessary for expression of *vanH*, -A, and -X - was amplified using genomic DNA from a known strain of VanA strain *Enterococcus faecium* (A1221) as a template (Arthur, et al., *J. Bacter.*, 1992, 174:2582-2591). 5' and 3' primers were synthesized by

-26-

Gibco BRL (Rockville, MD). The primer sequences for the respective 5' and 3' *vanH* promoter primers as follows:

5'-CUA CUA CUA CUA CGA ATT CAA GAA CAC TGG-3' (SEQ ID NO:14)

5'-CAU CAU CAU CAU CCA ACC CTT TCT GTG AAA GGC ACC-3' (SEQ ID NO:15)

5 Polymerase chain reaction amplification was conducted through the use of a Perkin-Elmer 9600 thermocycler for 30 cycles of 94°C, 55°C, and 72°C for 30 seconds each. The resulting amplification product, termed *vanHP* (*vanH* promoter) was then subcloned into the plasmid, pAMP1 (Gibco BRL, Rockville, MD), using the Cloneamp™ (Gibco BRL, Rockville, MD) cloning protocol.

10 The *vanA* gene was amplified using the following primer pair and subcloning the product into pAMP1 to create a plasmid designated pAMP1-*vanA* antisense:

5'-CUA CUA CUA CUA CTC GAG GCT TAT CAC CCC TTT AAC GC-3' (SEQ ID NO:16)

5'-CAU CAU CAU CAU GGA GAC AGG AGC ATG AAT AG-3' (SEQ ID NO:17)

15 The polymerase chain reaction with these primers consisted of 30 cycles of 94° C, 55°C, and 72°C for 35 seconds each.

Enterococcal Electroporation

Transformation of the *Enterococcus faecalis* strains with pAM401, pAM401-*vanHP*, or pAM401-*vanHP-vanA* antisense was accomplished via electroporation with a Biorad Gene
20 Pulser™ (Friesenegger, et al., *FEMS Microbiol. Letter*, 1991;79:323-328). In this procedure, 40 ul of electrocompetent enterococci were combined in a sterile 0.1 cm electroporation cuvette with 2 µl of purified plasmid DNA. The electroporation apparatus settings were 1.50 volts and 400 ohms. Under these conditions, resultant time constants are typically in the 9 millisecond range.

25 *Vancomycin Susceptibility Assays: Agar and Broth Dilutions*

Vancomycin susceptibilities were determined using the standard National Committee for Clinical Laboratory Standards (NCCLS) agar dilution protocol (National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A4. Wayne, PA: NCCCLS, 1997). In
30 this assay, the test antibiotic, in this case, vancomycin, was incorporated into Mueller Hinton II agar medium (Becton Dickenson) at two-fold dilutions ranging from concentrations of 0 µg/ml up to 512 µg /ml. The agar was then poured into respective sterile plates. Bacterial strains were then inoculated onto the agar plates and incubated at 35°C overnight. The

-27-

minimum inhibitory concentration (MIC) was then determined by the lowest concentration of antibiotic that completely inhibited colony growth.

Gene Expression-RT-PCR

A single colony of A407 with the pAM401-*vanHP-vanA* antisense construct was grown in brain-heart infusion (BHI) liquid media with sub-inhibitory concentrations of vancomycin (1 µg/ml) and chloramphenicol (10 µg/ml). Bacterial RNA was prepared using the Qiagen RNeasy® protocol for the isolation of total RNA (Qiagen Inc. Valencia, CA) modified to incorporate a step of treatment with RNase free DNase applied directly on the QIAamp® column (both Qiagen Inc. Valencia, CA). Then a modified Titan™ One tube RT-PCR protocol (Roche molecular biochemicals, Indianapolis, IN) was followed. The samples were then reverse transcribed and amplified by one-step RT-PCR. Each reaction mix contained template RNA (5µg), enzyme (either Titan enzyme mix, reverse and forward PCR primers and buffer components recommended for optimal enzyme activity. The forward (5'-CUA CUA CUA CUA CTC GAG GCT TAT CAC CCC TTT AAC GC -3' -SEQ ID NO:16) and the reverse primer (5'-CGA ATA CCG CAA GCG ACA G-3' -SEQ ID NO:25) were designed to amplify a 1.1 kb bacterial RNA sequence. The RT reaction was performed at 45°C for 60 min, followed by PCR in a Perkin Elmer Model 9600 Thermal Cycler with the following thermal profile: Initial denaturation: 95°C for 3 min then 35 cycles of denaturation (93°C, 15 s), annealing (55°C, 30 s), elongation (68°C, 70 s) and a final extension step (72°C, 7 min). Amplification products were analyzed by gel electrophoresis.

Results

Changes in Vancomycin Phenotypic Susceptibility

The vancomycin susceptibility of a *vanA* *Enterococcus faecalis* strain, A407, was assessed after electroporation with either pAM401; pAM401-*vanHP*; or pAM401-*vanHP-vanA* antisense. While the vancomycin minimum inhibitory concentration (MIC) remained at 128 µg/ml in A407 containing the pAM401 shuttle vector alone, the introduction of pAM401 with the *vanH* promoter decreased the vancomycin MIC to 16 – 32 µg/ml. The vancomycin MIC was further decreased in response to the pAM401 containing both the *vanH* promoter and the *vanA* antisense, typically in the 8 µg/ml range.

VanH promoter effect on vancomycin resistance

The p*VanR* binding domain within the *vanH* promoter has previously been characterized and consists of an approximate 80 bp region that is considered to have the capacity to bind multiple p-*VanR* molecules (Holman, et al., *Biochemistry*, 1994, 33:4625-

-28-

31). Therefore, it was reasoned that the introduction of an exogenous *vanH* promoter cloned into a recombinant enterococcal shuttle vector could increase the vancomycin susceptibility of a target VanA enterococcal isolate through the binding and sequestration of p*VanR* from the native *vanH* promoter. As an initial test of this hypothesis, pAM401 enterococcal shuttle
5 vectors with or without the *vanH* promoter were constructed and electroporated into a VanA strain of *E. faecalis* (A407). The successful transfer of the vectors by electroporation was confirmed through the purification of shuttle vector plasmids from the transformants followed by restriction digest analysis as well as by dideoxy-sequencing. To confirm that MIC changes in the transformants were not related to the loss of the VanA operon, the retention of the
10 resistance determinant gene cluster was confirmed by the polymerase chain reaction (PCR) amplification of relevant genes.

Using both agar and broth dilution methods to determine antibiotic susceptibilities after shuttle vector electroporation, the vancomycin MIC of A407 enterococci transformed with the shuttle vector containing the *vanH* promoter (pAM401-*vanHP*) demonstrated a four-
15 fold reduction in the MIC from 256 µg/mL to 64 µg/mL. In contrast and as expected, control A407 enterococci transformed with the pAM401 vector alone maintained the baseline (MIC of 256 µg/mL) resistance phenotype.

To further support that the vancomycin-resistance phenotypic changes seen with the transformation of pAM401-*vanHP* were due to a transcriptional activator binding decoy effect, the p*VanR* binding domain portion of the *vanH* promoter was amplified and cloned
20 into pAM401 (pAM401-p*VanR*-BD+). As a control, a shuttle vector containing a mutant p*VanR* binding domain-deficient *vanH* promoter (pAM401-p*VanR*-BD-) was also constructed. Consistent with the phenotypic effects seen with the entire *vanH* promoter, the transfer of the p*VanR* binding domain (pAM401-p*VanR*-BD+) into A407 enterococci
25 similarly resulted in a four-fold decrease in the vancomycin MIC to 64 µg/mL. As predicted, no vancomycin susceptibility change resulted from the introduction of the pAM401-p*VanR*-BD- vector.

Effects of vanH promoter-driven vanA antisense RNA expression

Recombinant pAM401 shuttle vectors were then created which contained a gene
30 cassette consisting of the *vanH* promoter and downstream *vanA* antisense gene (pAM401-*vanHP-vanA* antisense), a configuration in which antisense expression would thus be upregulated in parallel that of the native VanA operon in the presence of vancomycin. A control vector that expressed *vanH* promoter-driven *vanA* sense transcripts was also cloned

-29-

(pAM401-*vanHP-vanA* sense) and was electroporated into respective A407 VanA *E. faecalis*. The expression of the *vanH* promoter-*vanA* coding and antisense messenger RNA were confirmed by reverse transcriptase PCR (RT-PCR). In A407 *E. faecalis* electroporated with pAM401-*vanHP-vanA* antisense, the vancomycin MIC was reduced to a susceptible range, from 256 µg/mL to 2 µg/mL. As predicted, the MIC of A407 transformed with pAM401-*vanHP-vanA* sense remained at the baseline level of 256 µg/mL.

Discussion

A gene cassette targeting a key antibiotic resistance determinant of the clinically relevant Gram-positive bacterium, *Enterococcus*, has been constructed and consists of the enterococcal *vanH*-promoter driving the expression of a *vanA* antisense gene introduced in an enterococcal shuttle vector. The target gene, *vanA*, is a highly conserved component of a gene cluster that confers high-level resistance to vancomycin, a pivotal antibiotic used to treat infections caused by *Enterococcus* resistant to beta-lactam antibiotics. The *vanH* promoter employed in this construct is the same inducible enterococcal promoter which drives expression of the *vanA* resistance determinant expression (Figure 3). In such an arrangement, where both the resistance and anti-resistance determinant expression are driven by the same inducible promoter, the enterococcal transcriptional factor, phosphorylated *VanR* (p*VanR*), which induces the *vanH* promoter (Arthur, et al., *J. Bacter.*, 1992, 174:2582-2591), is at the same time, sequestered from the native *vanH* promoter, but also allows for induction of the anti-*vanA* antisense in parallel with the expression of the *vanHAX*. In short, this gene cassette inhibits vancomycin resistance both by an inducible antisense mechanism as well as by functioning as a transcriptional factor binding decoy (Figure 4). Reflective of such a dual mechanism, recombinant shuttle vectors containing the *vanH* promoter or the p*VanR* binding domain effected a partial restoration of vancomycin susceptibility, while full restoration of vancomycin susceptibility resulted with the introduction of a vector containing both *vanH* promoter and *vanA* antisense gene. More specifically, the introduction of a shuttle vector containing the *vanH* promoter alone into a vancomycin-resistant, *vanA*-containing *Enterococcus faecalis* resulted in up to a 16-fold reduction of the minimum inhibitory concentration for vancomycin while a shuttle vector containing both *vanH* promoter and *vanA* antisense increased vancomycin susceptibility even further (approximately 32-fold).

Given the increasingly important role of drug-resistant Gram-positive bacteria such as vancomycin-resistant *Enterococcus* as a cause of significant human disease, combined with a

-30-

dearth of effective pharmacological therapeutic options for this pathogen, novel strategies as described above, have several potential applications for (1) the treatment primary infections (2) the eradication of vancomycin-resistant *Enterococcus* from areas which are frequently colonized (e.g. intensive care units, dialysis units, individual patient's bowel flora, the agricultural setting) and (3) as a laboratory tool for the study of antibiotic resistance gene function and pathogenesis.

Recombinant shuttle vectors which target other genes in the *vanA* operon such as *vanX*, as well as polycistronic vectors which contain genetic elements designed to interfere with multiple VanA operon functions (e.g. *vanA*, *vanH*, and *vanX*), can be constructed using routine experimentation and no more than ordinary skill in the art. Given that an operon analogous to that associated with the VanA phenotype also forms the genetic basis for class B (VanB) vancomycin resistance, analogous compositions against Class B (VanB), as well as other classes of vancomycin resistance operons and genes can be developed as described above. For example, a *vanX* antisense strategy analogous to the *vanA* antisense strategy was also tested, resulting in lowering vancomycin MICs to the 2 µg/ml range.

Such compositions optimally include gene delivery systems such as bacteriophage, highly efficient transconjugative plasmids, and peptide-nucleic acids.

Detailed Description of the Drawings

Figure 1. The VanA vancomycin resistance operon. *vanR* represents a response regulator which, after phosphorylation, activates the *vanH* promoter which results in activation of *vanH*, *vanA*, and *vanX* transcription; *vanS*, a signal sensor, is responsible for the inducibility of the operon by glycopeptide antibiotics;; the *vanH* gene product is a dehydrogenase that generates lactate from pyruvate; *vanA* codes for a ligase which preferentially synthesizes D-ala-D-lac; *vanX* codes for a dipeptidase which degrades the native D-ala-D-ala produced by the wildtype ligase; *vanY* is a carboxypeptidase which removes terminal alanines; *vanZ* is responsible for increased resistance to teicoplanin.

Figure 2. Maps of the shuttle vectors and relevant cloning sites. (A) The parent vector, pAM401. This vector is composed of both *Enterococcus faecalis* (shaded half on right) and *Eschericia coli* (bold portion on left) components. The *cat* region is the chloramphenicol acetyl-transferase gene. The *tet* region is the tetracycline resistance gene. (B) The *vanH* promoter insertion. (C) The *vanA* antisense insertion.

-31-

Figure 3. The proposed nucleic acid binding decoy mechanism by which the observed vancomycin minimum inhibitory concentrations are reduced with the introduction of the pAM401 shuttle vector with the *vanH* promoter alone.

Figure 4. A schematic of the proposed mechanism-of-action of the pAM401-*vanH*
5 promoter-*vanA* antisense recombinant shuttle vector.

All terms used herein have their conventional meaning unless otherwise indicated.

All patents and other documents disclosed in this application are incorporated in their entirety herein by reference.

10 While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

What is claimed is followed by the Abstract and a Sequence Listing.

15 We claim:

-32-

Claims

1. A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising:
introducing into the organism at least one anti-sense vancomycin resistance molecule under conditions to inhibit expression of a vancomycin resistance gene.
2. The method of claim 1, wherein the vancomycin resistant organism is selected from the group consisting of the Gram-positive bacteria, *Enterococcus faecalis* and *Enterococcus faecium*, and other Gram-positive bacteria such as *Staphylococcus species*, and *Streptococcus species*, to which these organisms have the potential of transferring resistance determinants.
3. The method of claim 1, wherein the vancomycin resistant organism is a Gram-positive bacteria.
4. The method of claim 3, wherein the Gram-positive bacteria is an enterococcus.
5. The method of claim 1, wherein the vancomycin resistant organism is selected from the group consisting of a VanA resistant organism, a VanB resistant organism, a VanC resistant organism, and a VanD resistant organism.
6. The method of claim 1, wherein the vancomycin resistant organism is a vanA resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanA* anti-sense molecule, a *vanR* antisense molecule, a *vanS* anti-sense molecule, a *vanH* anti-sense molecule, a *vanX* anti-sense molecule, a *vanY* anti-sense molecule and a *vanZ* anti-sense molecule.
7. The method of claim 1, wherein the vancomycin resistant organism is a VanB resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanRB* anti-sense molecule, a *vanSB* anti-sense molecule, a *vanYB* anti-sense molecule, a *vanW* anti-sense molecule, a *vanHB* anti-sense molecule, and a *vanXB* anti-sense molecule.

-33-

8. The method of claim 1, wherein the anti-sense vancomycin resistant organism is a VanC resistant organism.
9. The method of claim 1, wherein the vancomycin resistant organism is a VanD resistant organism and the anti-sense vancomycin resistance molecule is selected from the group consisting of a *vanD* anti-sense molecule, a *vanRD* anti-sense molecule, a *vanSD* anti-sense molecule, a *vanYD* anti-sense molecule, a *vanHD* anti-sense molecule, and a *vanXD* anti-sense molecule.
10. The method of claim 1, wherein the anti-sense vancomycin resistance molecule is a *vanA* antisense molecule selected from the group consisting of:
 - an antisense molecule that hybridizes to the complete *vanA* gene sequence; and
 - an antisense molecule that hybridizes to a conserved region of the *vanA* gene sequence.
11. The method of claim 10, wherein the *vanA* antisense molecule hybridizes to a conserved region of the *vanA* gene including from 10 to 30 nucleotides.
12. The method of claim 11, wherein the *vanA* gene encodes an enzyme and the *vanA* antisense molecule hybridizes to a region of the *vanA* gene which encodes an active site of the ligase.
13. The method of claim 1, wherein introducing the anti-sense vancomycin resistance molecule comprises contacting the vancomycin resistant organism with at least one vector comprising one or more "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes.
14. The method of claim 13, wherein the vector is selected from the group consisting of: an enterococcal shuttle vector, an enterococcal or any other species or strain of bacteriophage; the nucleic acid portion of a peptide nucleic acid molecule; an enterococcal conjugative transposon or a pheromone-responsive plasmid.

-34-

15. The method of claim 14, wherein the vector is an enterococcal shuttle vector.
16. The method of claim 13, wherein the vector contains a single copy of a *vanA* antisense molecule.
17. The method of claim 13, wherein the vector contains multiple copies of a *vanA* antisense molecule.
18. The method of claims 16 or 17, wherein the vector comprises a *VanR*-responsive promoter operatively coupled to the *vanA* antisense molecule.
19. The method of claim 1, wherein the anti-sense vancomycin resistance molecule is a *vanX* antisense molecule selected from the group consisting of:
 - an antisense molecule that hybridizes to the complete *vanX* gene sequence; and
 - an antisense molecule that hybridizes to a conserved region of the *vanX* gene sequence.
20. A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising:
 - enhancing expression of a *vanH* promoter in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the *vanH* promoter is not operatively coupled to a vancomycin resistance gene of the organism.
21. The method of claim 20, wherein the *vanH* promoter is operatively coupled to an antisense vancomycin resistance molecule.
22. The method of claims 20 or 21, wherein the *vanH* promoter is contained on an enterococcus vector and enhancing expression comprises introducing into the organism an amount of the vector to express an amount of the *vanH* promoter sufficient to bind to phosphorylated *VanR* and thereby reduce vancomycin resistance in the organism.
23. The method of claim 20, further comprising co-administering into the organism an antisense vancomycin resistance molecule operatively coupled to a *vanH* promoter.

-35-

24. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NOs:1-13.
25. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID NOs:5-13.
26. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs:5-10.
27. A vector comprising an isolated nucleic acid molecule of any of claims 24, 25 or 26.
28. The vector of claim 27, further comprising a *vanH* promoter operatively coupled to the isolated nucleic acid molecule.
29. An isolated vancomycin resistant organism comprising a vector of claim 27 or 28.

Figure 1.







Figure 2.







-1-

SEQUENCE LISTING

<110> Beth Israel Deaconess Medical Center, Inc.
 Inouye, Roger T.
 Torres-Viera, Carlos
 Moellering, Robert
 Gold, Howard
 Eliopoulos, George M.

<120> METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC
 SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT ENTEROCOCCUS

<130> B0662/7036WO/ERP/KA

<150> U.S. 60/149,313

<151> 1999-08-17

<160> 39

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 10851

<212> DNA

<213> Enterococcus faecium

<400> 1

ggggtagcgt	cagg	aaatg	cggatttaca	acgctaagcc	tattttcctg	acgaatccct	60
cgtttttaac	aacgttaaga	aagtttttagt	ggctcttaaag	aatttaataga	gactactttc		120
tctgagttaa	aatggtattc	tcctagtaaa	ttaatatggt	cccaacctaa	gggcgacata		180
tggtgtaaca	aatcttcatt	aaagctacct	gtccgttttt	tatattcaac	tgctgttggt		240
aggtggagag	tattccaaat	acttatagca	ttgataatta	tgtttaaagc	actggctctt		300
tgcaattgat	gctgtatggt	gcgttctcta	agctcacctt	gttttccgaa	gaaaatagct		360
cttgccaatc	cattcatggc	ttctccttta	ttcaatcctc	tttgatattt	tcttcttaat		420
gattcatccg	atatataatt	caaaataaag	atcgtttttt	ctattcggcc	catctcacgt		480
aaggctgtag	ctaagctggt	ttgtcttgaa	taggaacctc	gcttcccat	aataagggat		540
gctgaaactg	ttccctccct	tatagaatga	gctaatacga	aaacatcctc	ataattttct		600
ttaatgacct	tgtattttat	ttgtccacgt	aaaatggctt	ctagttttgg	atactcactt		660
gctttatcta	tcgtaaataa	ttttgagtc	gataaaatccc	ttattcttgg	ggcaaattta		720
aatcctaata	aatgagtcag	tccgaatatt	tggtcagtg	aaccggcagt	gtctgtataa		780
tgttcctcta	tgtttagatc	cgtctcatga	tgtaacaaac	catccaaaac	atgaatcgca		840
tctcttgaat	tagtatgaat	aatctttgtg	tagtaagaag	agaattgatc	acttgtaaat		900
cggtagatgg	tggtcccttt	tccagttcca	taatgtggat	ttgcatctgc	atgtagtgat		960
gaaacaccta	gctgcattct	cataccatct	gacgaagatg	ttgtaccgtc	gccccaatag		1020
aaaggcaatt	gtaatttatg	atgaaagttt	actaatatgg	cttgggcttt	attcatggca		1080
tcttcataca	tgcgccattg	agatacattg	gctagttgct	tatatgtaag	tccgggtgtg		1140
gcttcggcca	tcttgctcaa	gccaatattc	attcccattc	ctaaaagggc	agccatgata		1200
atgattgttt	cttccttata	tggttttcga	ttattggaag	catgagtga	ttgtcatga		1260
aatcctgtta	tatgggccac	atccatgagt	aaatcagtta	attttattct	tggtagcatc		1320
tgataaaggc	ttgcactaaa	tttttttgct	tcttctggaa	catctttttc	taagcgtgca		1380
agtgatagct	ttcctttttc	aagagaaacc	ccatctaact	tattggaatt	ggcagctaac		1440
cactttaacc	tttcattaaa	gctgctgggt	ctctccgtta	tataatcttc	gaatgataaa		1500
ctaactgata	atctcgtatt	ccccttcgat	tgattccatg	tatcttccga	aaacaaatat		1560
tcttcaaaat	ccctatatgt	tctgctgcca	acaatggaaa	catctcctgc	ccgaacatgc		1620
tcccgaagtt	gtttaaacc	agccatttca	tagtaatgac	gattaattgt	tgtaccatca		1680
tcctcgtata	aatgtctttt	ccatcgtttt	gaaataaaat	ccacaggtga	gtcatcaggc		1740
acttttcgct	ttccagattc	gttcattcct	cggataatct	caacagcttg	taaaagtggc		1800

-2-

tcatttgcct	ttgtagaatg	aaattccaat	actcttaata	gcgttggcgt	atattttctt	1860
agtgaataaa	accgtttttg	cagtaagtct	aaataatcat	agtcggcagg	acgtgcaagt	1920
tcctgagcct	cttctactga	agagacaaaag	gtattccatt	caataaccga	ttctaaaacc	1980
ttaaaaacgt	ctaatttttc	ctctcttgct	ttaattaatg	cttgtccgat	gttcgtaaag	2040
tgtataaact	tctcatttag	ctttttaccg	ttttgtttct	ggatttcctc	ttgagcctta	2100
cgaccttttg	ataacaaact	aagtatttgc	ctatcatgaa	tttcaaacgc	tttatccggt	2160
agctcctgag	taagttgtaa	taaatagatg	gttaatatcg	aataacgttt	attttcttga	2220
aagtcacgga	atgcatacgg	ctcgtatctt	gagcctaagc	gagacagctg	caacaggcgg	2280
ttacggtgca	aatgactaat	ttgcactggt	tctaaatcca	ttcctcgat	gtattcgagt	2340
cgttctatta	tttttagaaa	agtttcgggt	gaaggatgac	ccggtggctc	ttttaaccaa	2400
cccaatatcg	ttttattgga	ttcggatgga	tgctgcgagg	taataatccc	ttcaagcttt	2460
tcttttggct	catttgtag	agatttacta	accgtattaa	atagcttctt	ttcagccatt	2520
gcccttgctt	cccacaccat	tctttcaagt	gtagtgatag	caggcagtat	aattttgttt	2580
tttcttagaa	aatctatgca	ttcatgcagt	agatgaatgg	catcaccatt	ttccaaagct	2640
aattgatgaa	ggtacttaaa	tgctattcga	tattcactca	gggtaaaagt	tacaaagtcg	2700
tattcacttc	gaatttcttt	caaagtatcc	caaagtgtat	tttccctttg	aggataatga	2760
tcaagcgagg	atggactaac	accaatctgt	ttcgatatat	attgtatgac	cgaatctggg	2820
atgcttttga	tatgagtgtg	tggccaaccg	ggataccgaa	gaacagctaa	ttgaacagca	2880
aatcctaaac	ggttttcttc	cctccttcgc	ttattaacta	tttctaaatc	ccgtttggaa	2940
aaagtgaagt	aggtccccag	tatccattca	tcttcaggga	tttgcataaa	agcctgtctc	3000
tgttccgggt	taagcaattc	tctacctctc	gcaattttca	ttcagtatca	ttccatttct	3060
gtattttcaa	tttattagtt	caattatata	tcaatagagt	gtactctatt	gatacaaatg	3120
tagtagactg	ataaaatcat	agttaagagc	gtctcataag	acttgtctca	aaaatgaggt	3180
gatattttgc	ggaaaatcgg	ttatatctgt	gtcagttcga	ctaaccagaa	tccttcaaga	3240
caatttcagc	agttgaacga	gatcggaatg	gatattatat	atgaagagaa	agtttcagga	3300
gcaacaaagg	atcgcgagca	acttcaaaaa	gtgtagacg	atttacagga	agatgacatc	3360
atztatgtta	cagacttaac	tcgaatcact	cgtagtacac	aagatctatt	tgaattaatc	3420
gataacatac	gagataaaaa	ggcaagttta	aaatcactaa	aagatacatg	gcttgattta	3480
tcagaagata	atccatacag	ccaattctta	attactgtaa	tggctgggtg	taaccaatta	3540
gagcgagatc	ttattcggat	gagacaacgt	gaagggattg	aattggctaa	gaaagaagga	3600
aagtttaaaag	gtcgattaaa	gaagtatcat	aaaaatcacg	caggaatgaa	ttatgcggta	3660
aagctatata	aagaaggaaa	tatgactgta	aatcaaattt	gtgaaattac	taatgtatct	3720
agggcttcat	tatacaggaa	attatcagaa	gtgaataatt	agccattctg	tattccgcta	3780
atgggcaata	tttttaaaga	agaaaaggaa	actataaaaat	attaacagcc	tcctagcgat	3840
gccgaaaagc	cctttgataa	aaaaagaatc	atcatcttaa	gaaattctta	gtcattttatt	3900
atgtaaatgc	ttataaattc	ggccctataa	tctgataaat	tattaagggc	aaacttatgt	3960
gaaaggggtg	taactatgag	cgataaaaata	cttattgttg	atgatgaaca	tgaaattgcc	4020
gatttggttg	aattatactt	aaaaaacgag	aattatacgg	ttttcaaata	ctataccgcc	4080
aaagaagcat	tggaaatgtat	agacaagctc	gagattgacc	ttgccatatt	ggacatcatg	4140
cttcccggca	caagcggcct	tactatctgt	caaaaaataa	gggacaagca	cacctatccg	4200
attatcatgc	tgaccgggaa	agatacagag	gtagataaaa	ttacagggtt	aacaatcggc	4260
gcggatgatt	atataacgaa	gccctttcgc	ccactggagt	taattgctcg	ggtaaaggcc	4320
cagttgcgcc	gatacaaaaa	attcagtggg	gtaaaaggagc	agaacgaaaa	tggtatcgtc	4380
cactccggcc	ttgtcattaa	tgtaaacacc	catgagtgtt	atctgaacga	gaagcagtta	4440
tcccttactc	ccaccgagtt	ttcaatactg	cgaatcctct	gtgaaaacaa	ggggaaatgtg	4500
gttagtcccg	agctgctatt	tcatgagata	tggggcgacg	aatattttcag	caagagcaac	4560
aacaccatca	ccgtgcatat	ccggcatttg	cgcgaaaaaa	tgaacgacac	cattgataat	4620
ccgaaatata	taaaaaacgt	atgggggggt	ggttataaaa	ttgaaaaata	aaaaaaacga	4680
ctattccaaa	ctagaacgaa	aactttacat	gtatatcggt	gcaattgttg	tggtagcaat	4740
tgtattcgtg	ttgtatattc	gttcaatgat	ccgagggaaa	cttggggatt	ggatcttaag	4800
tattttggaa	aacaaatatg	acttaaatca	cctggacgcg	atgaaattat	atcaatatct	4860
catacggaa	aatatagata	tctttattta	tgtggcgatt	gtcattagta	ttcttattct	4920
atgtcgcgtc	atgctttcaa	aattcgcaaa	atactttgac	gagataaaata	ccggcattga	4980
tgactttatt	cagaacgaag	ataaacaat	tgagctttct	gcggaaatgg	atgttatgga	5040
acaaaagctc	aacacattaa	aacggactct	ggaaaaagcga	gagcaggatg	caaagctggc	5100
cgaacaaaga	aaaaatgacg	ttgttatgta	cttggcgcac	gatattaaaa	cgccccctac	5160
atccattatc	ggttatttga	gcctgcttga	cgaggctcca	gacatgccgg	tagatcaaaa	5220

-3-

ggcaaagtat	gtgcatatca	cgttggacaa	agcgtatcga	ctcgaacagc	taatcgacga	5280
gttttttgag	attacacggt	ataacctaca	aacgataacg	ctaacaaaaa	cgcacataga	5340
cctatactat	atgctggtgc	agatgaccga	tgaattttat	cctcagcttt	ccgcacatgg	5400
aaaacaggcg	gttattcacg	cccccgagga	tctgaccgtg	tccggcgacc	ctgataaact	5460
cgcgagagtc	tttaacaaca	ttttgaaaaa	cgccgctgca	tacagtgagg	ataacagcat	5520
cattgacatt	accgcggggc	tctccgggga	tgtggtgtca	atcgaattca	agaacactgg	5580
aagcatccca	aaagataagc	tagctgccat	atttgaaaag	ttctataggc	tggacaatgc	5640
tcgttcttcc	gatacgggtg	gcgcgggact	tggattggcg	attgcaaaag	aaattattgt	5700
tcagcatgga	gggcagattt	acgcggaaag	caatgataac	tatacgacgt	ttagggtaga	5760
gcttccagcg	atgccagact	tggttgataa	aaggagggtcc	taagagatgt	atataatttt	5820
ttaggaaaat	ctcaaggtta	tctttacttt	ttcttaggaa	attaacaatt	taatatataag	5880
aaacggctcg	ttcttacacg	gtagacttaa	taccgtaaga	acgagccgtt	ttcgttcttc	5940
agagaaagat	ttgacaagat	taccattggc	atccccgttt	tatttgggtg	ctttcacaga	6000
aagggttggg	cttaattatg	aataacatcg	gcattactgt	ttatggatgt	gagcaggatg	6060
aggcagatgc	attccatgct	ctttcgccct	gctttggcgt	tatggcaacg	ataattaacg	6120
ccaacgtgtc	ggaatccaac	gccaaatccg	cgcttttcaa	tcaatgtatc	agtgtgggac	6180
ataaatcaga	gatttccgcc	tctattcttc	ttgcgctgaa	gagagccggg	gtgaaatata	6240
tttctaccgc	aagcatcggc	tgcaatcata	tagatacaac	tgctgctaag	agaattggga	6300
tcactgtcga	caatgtggcg	tactcgccgg	atagcgttgc	cgattatact	atgatgctaa	6360
ttcttatggc	agtacgcaac	gtaaaaatcg	ttgtgcgctc	tgtggaaaaa	catgatttca	6420
ggttggacag	cgaccgtggc	aagggtactca	gcgacatgac	agttggtgtg	gtgggaacgg	6480
gccagatagg	caaagcgggt	attgagcggc	tgcgaggatt	tggatgtaaa	gtgttggctt	6540
atagtcgcag	ccgaagtata	gaggtaaaact	atgtaccgtt	tgatgagttg	ctgcaaaaata	6600
gcgatatcgt	tacgcttcat	gtgccgctca	atacgggatac	gcactatatt	atcagccacg	6660
aacaaatata	gagaatgaag	caaggagcat	ttcttatcaa	tactgggccc	gggtccactg	6720
tagataccta	tgagttgggt	aaagcattag	aaaacgggaa	actgggcccgt	gccgcattgg	6780
atgtattgga	aggagaggaa	gagtttttct	actctgattg	cacccaaaaa	ccaattgata	6840
atcaattttt	acttaaac .t	caaagaatgc	ctaacgtgat	aatacacacc	catacggcct	6900
attataccga	gcaagcgttg	cgtgataccg	ttgaaaaaac	cattaaaaaac	tgtttggatt	6960
ttgaaaggag	acaggagcat	gaatagaata	aaagttgcaa	tactgttttg	gggttgctca	7020
gaggagcatg	acgtatcggt	aaaatctgca	atagagatag	ccgctaacat	taataaagaa	7080
aaatacgagc	cgttatacat	tggaaattacg	aaatctgggtg	tatggaaaat	gtgcgaaaaa	7140
ccttgccggg	aatgggaaaa	cgacaattgc	tattcagctg	tactctcgcc	ggataaaaaa	7200
atgcacggat	tacttggtta	aaagaaccat	gaatatgaaa	tcaaccatgt	tgatgtagca	7260
ttttcagctt	tgcatggcaa	gtcaggtgaa	gatggatcca	tacaaggctc	gtttgaattg	7320
tcgggtatcc	cttttgtagg	ctgcgatatt	caaagctcag	caatttgtat	ggacaaatcg	7380
ttgacataca	tcgttgcgaa	aaatgctggg	atagctactc	ccgccttttg	ggttattaat	7440
aaagatgata	ggccgggtggc	agctacgttt	acctatcctg	tttttggtta	gccggcgctg	7500
tcaggctcat	ccttcgggtg	gaaaaaagtc	aatagcgcgg	acgaattgga	ctacgcaatt	7560
gaatcggcaa	gacaatatga	cagcaaaatc	ttaattgagc	aggctgtttc	gggctgtgag	7620
gtcggttgtg	cggtattggg	aaacagtgcc	gcgttagttg	ttggcgagggt	ggaccaaatc	7680
aggctgcagt	acggaatctt	tcgtattcat	caggaagtgc	agccggaaaa	aggctctgaa	7740
aacgcagtta	taaccgttcc	cgcagacctt	tcagcagagg	agcaggagcg	gatacaggaa	7800
acggcaaaaa	aaatatataa	agcgtctcgg	tgtagaggtc	tagcccgtgt	ggatatgttt	7860
ttacaagata	acggccgcac	tgtactgaac	gaagtcaata	ctctgcccg	tttcacgtca	7920
tacagtcggt	atccccgtat	gatggccgct	gcaggatttg	cacttcccga	actgattgac	7980
cgcttgatcg	tattagcggt	aaaggggtga	taagcatgga	aataggattt	acttttttag	8040
atgaaatagt	acacgggtgt	cgttgggacg	ctaaatatgc	cacttgggat	aatttcaccg	8100
gaaaaccggg	tgacgggtat	gaagtaaatac	gcattgtagg	gacatacgag	ttggctgaat	8160
cgcttttgaa	ggcaaaaagaa	ctggctgcta	cccaagggtta	cggattgctt	ctatgggacg	8220
gttaccgtcc	taagcgtgct	gtaaaactgtt	ttatgcaatg	ggctgcacag	ccggaaaaata	8280
acctgacaaa	ggaaaagtat	tatcccaata	ttgaccgaac	tgagatgatt	tcaaaaaggat	8340
acgtggcttc	aaaatcaagc	catagccgcg	gcagtgccat	tgatcttacg	ctttatcgat	8400
tagacacggg	tgagcttgta	ccaatggggg	gccgatttga	ttttatggat	gaacgctctc	8460
atcatgctgg	aaatggaata	tcatgcaatg	aagcgcaaaa	tcgcagacgt	ttgcgtccca	8520
tcatggaaaa	cagtggtgtt	gaagcatata	gcctcgaatg	gtggcactat	gtattaagag	8580
acgaaccata	ccccaatagc	tatttttgatt	tccccgttaa	ataaaactttt	aaccgttgca	8640

-4-

cggacaaaact	atataagcta	actcttttcgg	caggaaaccc	gacgtatgta	actgggttctt	8700
aggggaattta	tatatagtag	atagtagtga	agatgtaagg	cagagcgata	ttgcgggtcat	8760
tatctgcgtg	cgctgcggca	agatagcctg	ataataagac	tgatcgcata	gaggggtggt	8820
atttcacacc	gcccattgtc	aacaggcagt	tcagcctcgt	taaattcagc	atgggtatca	8880
cttatgaaaa	ttcatctaca	ttggtgataa	tagtaaatcc	agtagggcga	aataattgac	8940
tgtaatttac	ggggcaaaac	ggcacaatct	caaacgagat	tgtgccgttt	aaggggaaga	9000
ttctagaaat	atttcatact	tccaactata	tagttaagga	ggagactgaa	aatgaagaag	9060
ttgttttttt	tattgttatt	gttattctta	atatacttag	gttatgacta	cgttaatgaa	9120
gcactgtttt	ctcaggaaaa	agtcgaattt	caaaattatg	atcaaaatcc	caaagaacat	9180
ttagaaaata	gtgggacttc	tgaaaatacc	caagagaaaa	caattacaga	agaacagggt	9240
tatcaaggaa	atctgctatt	aatcaatagt	aaatatcctg	ttcgccaaga	aagtgtgaag	9300
tcagatatac	tgaatttatc	taaacatgac	gaattaaata	atggatacgg	gttgcttgat	9360
agtaatat	atatgtcaaa	agaaatagca	caaaaatttt	cagagatggg	caatgatgct	9420
gtaaaggggtg	gcgttagtca	ttttattatt	aatagtggct	atcgagactt	tgatgagcaa	9480
agtgtgcttt	accaagaaat	gggggctgag	tatgccttac	cagcagggtta	tagtgagcat	9540
aattcagggt	tatcactaga	tgtaggatca	agcttgacga	aaatggaacg	agcccctgaa	9600
ggaaagtggg	tagaagaaaa	tgcttgga	tacgggttca	ttttacgtta	tccagaggac	9660
aaaacagagt	taacaggaat	tcaatatgaa	ccatggcata	ttcgctatgt	tggtttacca	9720
catagtgcga	ttatgaaaga	aaagaatttc	gttctcgagg	aatatatgga	ttacctaaaa	9780
gaagaaaaaa	ccatttctgt	tagtgtaaat	ggggaaaaat	atgagatcct	ttattatcct	9840
gttactaaaa	ataccaccat	tcattgtg	actaatcttc	gttatgagat	atcaggaaac	9900
aatatagacg	gtgtaattgt	gacagtgttt	cccggatcaa	cacatactaa	ttcaaggagg	9960
taaggatggc	ggaatgaaac	caacgaaatt	aatgaacagc	attattgtac	tagcactttt	10020
ggggtaacgt	tagcttttta	attttaaacc	cacgttaact	aggacattgc	tatactaatg	10080
atacaactta	aacaaaagaa	ttagaggaaa	ttatattggg	aaaaatatta	tctagaggat	10140
tgctagcttt	atatttagtg	acactaatct	ggttagtgtt	attcaaatta	caatacaata	10200
ttttatcagt	atttaattat	catcaaagaa	gtcttaactt	gactccattt	actgctactg	10260
ggaatttcag	agagatgata	gataatgtta	taacttttat	tccatttggc	ttgcttttga	10320
atgtcaattt	taaagaaatc	ggattttttac	ctaagtttgc	ttttgtactg	gttttaagtc	10380
ttacttttga	aataattcaa	tttatcttcg	ctattggagc	gacagacata	acagatgtaa	10440
ttacaaatac	tggtggaggc	tttcttggac	tgaaattata	tggtttaagc	aataagcata	10500
tgaatcaaaa	aaaatttagac	agagtattata	ttttttagag	tatacttttg	ctcgtattat	10560
tgctcgttta	ccgtacccat	ttaagaataa	attacgtgta	agatgtctaa	atcaagcaat	10620
ctgatctttc	atacacataa	agatatggaa	tgaattggat	tagatggaaa	acgggatgtg	10680
gggaaactcg	cccgtagggtg	tgaagtggag	ggaaaaccgg	tgataaagta	aaaagcttac	10740
ctaactat	agtaacaaag	aaagcccaat	tatcaatttt	agtgtctgag	aattgggtctc	10800
tttaataaat	ttccttaacg	ttgtaaatcc	gcattttcct	gacggtaccc	c	10851

<210> 2

<211> 7160

<212> DNA

<213> Enterococcus faecalis

<400> 2

tttaaacggt	atatttcgga	agaactgtgg	aaacggctta	tctctgtaaa	atggggcatt	60
acagggcggt	gggtacaaaa	gctctgcat	ggacgattaa	aatccgaaaa	gaaatcgctt	120
tgaaactaca	gggaaactac	agactgttat	gttatcttct	taaatggagg	gatttttatg	180
tcgatacgaa	ttctacttgt	cgaggatgat	gatcatatct	gcaatacagt	aagggcgttt	240
ttggctgaag	caagatatga	ggtggatgcc	tgacagatg	gaaacgaagc	acacaccaag	300
ttctatgaaa	acacctatca	actgggtatt	cttgatatta	tgctgcccgg	tatgaatggg	360
catgaacttc	tacgtgaatt	tcgggcgcaa	aatgatcccc	ccattctgat	gatgacagcc	420
ctgtcggatg	acgaaaacca	aatccggcg	tttgatgcag	aggcagacga	ctatgtaaca	480
aagccattca	agatgcggat	tttactaaag	cgggtggaag	ccctgttacg	gcgcagcggt	540
gcgctggcaa	aggaatttcg	tgtgggcagg	ctgacacttc	tgccggagga	ttttagggtta	600
ctttgtgacg	gtacggagct	gcccctgaca	cgaaaagaat	ttgaaatcct	tttgctgctg	660

-5-

gtgcagaaca	aaggcagaac	cttaacccat	gaaatcattt	tgtcccgcac	atggggatat	720
gactttgacg	gtgatggcag	cacagtccac	actcatatca	aaaatctgcg	ggcgaagctg	780
ccggaaaata	tcatcaaaac	catccgcggt	gtaggttacc	gattggagga	atcattataa	840
tggaaagaaa	agggattttc	attaaggttt	tttcctatac	gatcattgtc	ctgttactgc	900
ttgtcgggtg	aacggcaaca	ctgtttgcac	agcaatttgt	gtcttatttc	agagcgatgg	960
aagcacagca	aacagtaaaa	tcctatcagc	cattgggtgga	actgattcag	aatagcgata	1020
ggcttgatat	gcaagagggtg	gcagggctgt	ttcactacaa	taaccaatcc	tttgagtttt	1080
atattgaaga	taaagaggga	agcgtactct	atgccacacc	gaatgccgat	acatcaaata	1140
gtgttaggcc	cgactttctt	tatgtggtac	atagagatga	taatatttcg	attgttgctc	1200
aaagcaaggc	aggtgtggga	ttgctttatc	aagggctgac	aattcgggga	attgttatga	1260
ttgcgataat	ggttgtattc	agccttttat	gcgcgtatat	ctttgcgcgg	caaatagcaa	1320
cgccgatcaa	agccttagcg	gacagtgcga	ataaaatggc	aaacctgaaa	gaagtaccgc	1380
cgccgctgga	gcgaaaggat	gagcttggcg	cactggctca	cgacatgcat	tccatgtata	1440
tcaggctgaa	agaaaccatc	gcaaggctgg	aggatgaaat	cgcaaggga	catgagttgg	1500
aggaaacaca	gcgatatttc	tttgccggcag	cctctcatga	gttaaaaacg	cccatcgcg	1560
ctgtaagcgt	tctgttggag	ggaatgcttg	aaaatatcgg	tgactacaaa	gaccattcta	1620
agtatctgcg	cgaatgcac	aaaatgatgg	acaggcagg	caaaaccatt	tccgaaatac	1680
tggagcttgt	cagcctgaac	gatgggagaa	tcgtaccat	agccgaaccg	ctggacatag	1740
ggcgcacggt	tgccgagctg	ctacccgatt	ttcaaaccct	ggcagaggca	aacaaccagc	1800
ggttcgtcac	agatattcca	gccggacaaa	ttgtcctgtc	cgatccgaag	ctgatccaaa	1860
aggcgctatc	caatgtcata	ttgaatgcgg	ttcagaacac	gccccaggga	ggtagaggtac	1920
ggatatggag	tgagcctggg	gctgaaaaat	accgtcttct	cgttttgaac	atgggcgttc	1980
acattgatga	tactgcactt	tcaaagctgt	tcatcccat	ctatcgcat	gatcaggcgc	2040
gaagcagaaa	aagtgggcga	agcggtttgg	ggcttgccat	cgtacaaaaa	acgctggatg	2100
ccatgagcct	ccaatatgcg	ctggaaaaa	cctcagatgg	cgttttgttc	tggtctggatt	2160
taccgcccac	atcaacacta	taaatattta	aaacttaaat	gattttgacc	gacagggtata	2220
accctgccgg	tctttttgtt	tttcgccggt	acaggaaaaa	tacagattga	ctacagggaa	2280
agtacagata	cgcttgccat	aataacaatc	gtaccagcca	caaatacgtag	ttttattgca	2340
aaggaggcat	tcaatcaa	ggaaaaaagc	aactatcatt	ccaatgtgaa	tcatcacaaa	2400
cggcataatga	aacaatctgg	ggaaaaacgg	gcttttctat	gggcgttcat	tatctcgttc	2460
acagtctgca	cgctgttttt	gggttgagga	ttgggttccg	tattggaggc	aacacagcta	2520
ccgcccattcc	ctgcaactca	tacaggcagc	gggactgggtg	tagcggagaa	tccagaggaa	2580
aacactcttg	ccaccgccaa	agaacaggga	gatgaacagg	aatggagcct	gatttttagtg	2640
aacaggcaga	accccatccc	cgcccagtac	gatgtggaac	ttgagcagct	gtcaaagtgt	2700
gagcggatag	acattcggat	ttctccctac	ctccaggatt	tgtttgatgc	cgcaagagct	2760
gatggagttt	acccgattgt	cgcatccgga	taccggacaa	cagaaaaaca	gcaagaaatc	2820
atggatgaaa	aagtcgccga	atacaaggcg	aaaggctaca	cctctgcaca	ggctaaagcg	2880
gaagcagaaa	cttgggtggc	cgtgccggga	acaagcgagc	atcagcttgg	tcttgctgtg	2940
gatatcaatg	cggatggaat	tcatcaacc	ggcaacgagg	tttacagatg	gctggatgaa	3000
aacagctatc	gctttggttt	tattcgccgc	taccgcgcag	acaagacaga	gataaccggt	3060
gtgagcaacg	agccgtggca	ttaccgatat	gtcggcatcg	aagctgccac	aaagatatac	3120
caccaagggc	tttgccctga	ggaatatatta	aacacagaaa	aatgagaaaa	ggatataatg	3180
ctatgaacag	aaaaagattg	acacagcgct	tcccgttcc	gcttccaatg	agacaagcgc	3240
agagaaaaat	atgcttttat	gcgggaatga	gatttgacgg	ctgttgctat	gcacagacga	3300
taggagaaaa	aacgcttccc	tatttgctct	ttgaaacgga	ttgtgcgtta	tacaaccaca	3360
ataccggatt	tgacatgata	taccaagaaa	acaagggtgt	caacttaaag	ctggcggcaa	3420
agaccttaaa	cggcctattg	ataaaaccgg	gggaaacctt	ttctttctgg	cggtctgtac	3480
gccatgcgga	caaagatacc	ccctataaag	acggccttac	ggtaggccaat	ggtaagctca	3540
ccaccatgtc	gggcggcggt	atgtgccaga	tgagcaattt	actattttgg	gtgttcctgc	3600
atacgccatt	gacaattatc	cagcgcagcg	gtcacgtagt	aaaggagttt	ccagagccaa	3660
acagtgcaga	gatcaaagg	gtggatgcaa	ccatctcaga	gggttggtat	gatttaaaag	3720
tgcgaaacga	taccgactgc	acctaccaa	tatgggtgac	cctagatgat	gagaaaaatc	3780
tcggtcaggt	gttcgcccac	aaacagcctc	aagcattata	caaaattgca	aacggcagta	3840
ttcagtatgt	ccgtgaaagt	ggcgggattt	atgaatatgc	caagggtgaa	cggatgcaag	3900
ttgccttagg	taccggggaa	ataatagatt	gcaagctgct	ttatacaaac	aaatgcaaaa	3960
tctgctatcc	cctcccggaa	agtgtggata	ttcaggaggc	gaaccaatga	gaaaaagtat	4020
gggcattact	gtttttggat	gcgagcagga	tgaggcaaat	gctttccgca	ccttatcacc	4080

-6-

agatttttcat	attatcccta	cgctgatcag	tgatgcgata	tcggcagaca	acgcaaaatt	4140
ggcgcgtggc	aatcaatgca	ttagcgtagg	ccataagtc	gagggtttccg	aggcgacaat	4200
tcttgcgctg	agaaaggctg	gggtaaaata	catttctacc	cgagcatcg	gctgcaatca	4260
cattgatacg	actgccgccg	agagaatggg	gatctcggtt	ggcacagttg	cgtattcgcc	4320
ggacagcggt	gcggtattatg	ctttgatgct	gatgctgatg	gccatacggg	gtgcaaagtc	4380
caccatacac	gccgtggcgc	aacaaaattt	cagactggat	tgtgtccggg	ggaaagagct	4440
gcgggatatg	actgtgggag	ttatttgaac	cggccatata	gggcaagcgg	tcgtcaaaaag	4500
gctgcgggga	tttggatgcc	gtgtgctagc	ctatgataac	agccgaaaaa	ttgaggcaga	4560
ttatgtccag	cttgatgagc	ttctaaaaaa	cagcgatatt	gttacgctcc	atgtgccgct	4620
ttgtgcggt	acccgccatc	tgatcgccca	gagcgaaatc	ggagagatga	agcaaggcgc	4680
atttttaatc	aacactgggc	gcggggcgct	gttcgatacc	gggtcgctgg	tggaggcact	4740
gggaagcggg	aagctggcgc	gtgcggcact	ggatgtgttg	gagggcgagg	atcagtttgt	4800
ttataccgac	tgctcgcaga	aagtgtctga	ccatcccttt	ttgtcgcagc	tcctaaggat	4860
gccaaatgtg	atcatcacac	cccatacggc	gtactacacc	gagcgtgtgc	tgcgagatac	4920
cacagaaaaa	acaatcagga	attgtcttaa	ctttgaaagg	agtttacagc	atgaataaaa	4980
taaaagtgcg	aattatcttc	ggcggttgct	cggaggaaca	tgatgtgtcg	gtaaaaatccg	5040
caatagaaat	tgctgcgaac	attaatactg	aaaaattcga	tcgcactac	atcggaatta	5100
caaaaaacgg	cgtatggaag	ctatgcaaga	agccatgtac	ggaatgggaa	gccgatagtc	5160
tccccgccat	attctccccg	gataggaaaa	cgcattggtc	gcttgctcatg	aaagaaagag	5220
aatacgaaac	tcggcgctatt	gacgtggctt	tcccggtttt	gcatggcaaa	tgcggggagg	5280
atggtgcgat	acaggtctcg	tttgaattgt	ctggtatccc	ctatgtaggc	tgcgatatcc	5340
aaagctccgc	agcttgcatg	gacaaatcac	tggcctacat	tcttacaaaa	aatgcgggca	5400
tcgccgtccc	cgaatttcaa	atgattgaaa	aaggtgacaa	accggaggcg	aggacgctta	5460
cctaccctgt	ctttgtgaag	ccggcacggg	caggttcgtc	ctttggcgta	accaaagtaa	5520
acagtacgga	agaactaaac	gctgcgatag	aagcagcagg	acaatatgat	ggaaaaatct	5580
taattgagca	agcgatttcg	ggctgtgagg	tcggctgcgc	ggtcatggga	aacgaggatg	5640
atttgattgt	cggcgaaagt	gatcaaatcc	ggttgagcca	cggatatctc	cgcatccatc	5700
aggaaaaacga	gccggaaaaa	ggctcagaga	atgcgatgat	tatcgttcca	gcagacattc	5760
cggtcgagga	acgaaatcgg	gtgcaagaaa	cggcaagaaa	agtatatcgg	gtgcttggat	5820
gcagaggggt	tgctcgtgtt	gatctttttt	tgcaggagga	tggcggcatc	gttctaaacg	5880
aggtaatac	cctgcccggt	tttacatcgt	acagccgcta	tccacgcgatg	gcggctgccg	5940
caggaatcac	gcttcccgcg	ctaattgaca	gcctgattac	attggcgata	gagaggtgac	6000
ccgtatggaa	aatgggtttt	tgttttttaga	tgaatgttg	catggtgttc	gttgggatgc	6060
caagtacgct	acatgggata	acttcacggg	aaaaccagtg	gatgggtatg	agggtgaatcg	6120
catcatcggc	acaaaggccg	tggcgcttgc	tctgcgcgaa	gcacaaatcc	atgcggcacg	6180
ccttggctac	ggcttgcttt	tatgggatgg	atatcggcca	aaatctgcgg	tggactgttt	6240
cctgcgttgg	gcggcgcgagc	cggaggacaa	cctcacaaaa	gaaaaaatatt	accccaatat	6300
tgagcgagcc	gagttgatta	caaagggtcta	tgtggcctca	caatccagcc	atagccgtgg	6360
aagcacaatt	gatcttacgc	tctaccactt	ggatacaggg	gaacttgttt	caatgggaag	6420
caacttcgat	tttatggacg	aacggtcgca	ccatacagca	aaagggatag	ggaatgcaga	6480
ggcacaaaaa	cgaagatgct	tgcgtaaaat	catggaaagc	agcggatttc	agtcctatcg	6540
ctttgaaatg	tggcactata	agttgattga	tgagccatac	cccgatacct	attttaattt	6600
tgctgtttca	taatgaaagt	atttgatttt	ctaattatgt	ataagttggc	tacaaattac	6660
ttagtatttc	atcagaccaa	ttactctctt	gtttacagaa	aaattctgcg	ctgatggaat	6720
ctgctttatt	atgcgggcga	aaaatgaaat	tgaccatatt	ttttcagaac	tttactctgt	6780
accgaattgc	ctgcaaaagc	cttattttta	gctgaaagtt	caggaattgc	ttttgttttt	6840
gtgtatgccc	ctcgtgattt	gtacacctat	cttaattggc	tttgcaattc	tcattccgta	6900
tctctgcttt	aagaatttgg	aaaaacgaag	cattgtgaat	cggctgcggg	cagagcaaaa	6960
agagaaccag	cagaaacaag	tcgttcttgc	tctgctgatt	cactcggaac	tgtttgattc	7020
gggttttcgt	tgaaggtcaa	gtagctgctc	tgctcaggaag	tccagtgtgt	tcagcagaat	7080
ctgctgattg	tcacggttgc	atgactgaaa	ttttcccatg	aaacgctgga	gttcttcac	7140
ctcaatagag	tttgaagctt					7160

<210> 3

<211> 1086

-7-

<212> DNA

<213> *Enterococcus casseliflavus*

<400> 3

gtaagaatcg	gaaaagcggga	aggaagaaaa	acatgaaaaa	aatcgccatt	atTTTTtggag	60
gcaattcacc	ggaatacacc	gtttcttttag	cttcagcaac	tagcgcaatc	gaagcactcc	120
aatcatctcc	ctatgactac	gacctctctt	tgatcgggat	cgccccagat	gctatggatt	180
ggtacttgta	tacaggagaa	ctggaaaaca	tccgacaaga	cacgtgggtg	ttggatacga	240
aacataaaca	gaaaatacag	ccgctattcg	aaggaaacgg	ctTTTTggcta	agtgaagagc	300
agcaaacgtt	ggtacctgat	gttttatttc	ccattatgca	tggcaaatac	ggggaagatg	360
gcagtatcca	aggattgttt	gaattgatga	agctgcctta	tgtaggctgc	gggggtggcag	420
gttctgcctt	atgtatgaac	aaatggctgc	tgcacaaagc	tgacgcagcc	attggcgtac	480
aaagtgtctc	tacgattctc	ttgacaaatc	aagccaacca	gcaagaacaa	atcgaaagctt	540
ttatccagac	ccatggcttc	ccagttttct	ttaagcctaa	tgaagcgggc	tcctcaaaag	600
ggatcactaa	agtcacctgc	gttgaagaaa	tcgcttctgc	cttaaaagaa	gcctttactt	660
attgttccgc	agtgtctcta	caaaaaaata	ttgccgggtg	tgagatcggt	tgccggtattt	720
tgggcaacga	ctctttgact	gtcgggtgct	gtgacgccat	ttcattagta	gacggctttt	780
tcgattttga	agaaaagtac	cagctgatca	gcgcaaaaat	caccgtccct	gcgccattgc	840
ctgaaacgat	tgaaaccaag	gtcaaagaac	aagctcagct	gctctatcgt	agtcctgggc	900
ttaaaggtct	tgctcgcac	gacttttttg	tcacggagcg	aggagaacta	tacttgaatg	960
aatcaatac	tatgccgggc	tttacgagtc	actccgccta	tcctgccatg	atggcagcgg	1020
tcggcttatc	ctatcaagaa	ctactacaaa	aactgcttgt	cttagcaaa	gaggaagtca	1080
aatgag						1086

<210> 4

<211> 5781

<212> DNA

<213> *Enterococcus faecium*

<400> 4

attaatctgc	attgtttgtt	catatcgatt	ttgacacata	ataaagacag	attatcgcaa	60
tgtaaggagt	aatgcaatga	atgaaaaaat	cttagtggtt	gatgatgaaa	aagaattggc	120
cgacttagtt	gaagtatatc	tgaaaaacga	tggataatcc	gtttataaat	tttataatgg	180
caaggatgca	ctaaagtgtg	ttgaatccgt	ggaactggat	ttagccatat	tggatatcat	240
gcttccggat	gtagacgggt	ttcagatctg	ccagaaaaatc	cgggaaaagt	tttacttccc	300
tgttatcatg	ctgacagcaa	aagtggagga	cggggataaa	atcatgggac	tgtccgtggc	360
ggatgattat	attacaaagc	cgtttaaccc	gctggaagtg	gttgcgagag	ttaaaggcgca	420
gctgcggcag	tacatgcgg	acaagcagcc	cagcttaaa	caggaggctg	aatgcacaga	480
atacgatatc	agagggatga	caatcagcaa	gagcagccat	aagtgtatcc	tgtttggaaa	540
ggagattcag	ctgacgccaa	cggagttttc	gattcttttg	tatctgtgcg	agcgtcaggg	600
tacggttggt	tctacggagg	aattatttga	ggcagtatgg	ggtgaacgg	tttttgacag	660
caataatact	gtgatggcgc	atatcggg	gctccgggag	aaaatgaagg	aaccgtcaag	720
aaatccgaaa	tttataaaaa	ctgtgtgggg	agtgggatat	accattgaaa	aatagaaata	780
aaaccagtc	tgaagatgac	tatttacttt	ttaaaaacag	attgtccgtt	aaaatactgc	840
ttatgatggt	atattccatt	ctgattattg	cgggtgttta	tctgtttatc	ttaaaagata	900
atTTtTgcaa	tgtcgtggta	gccatttttag	acagctttat	ctatcatgat	cgggatgagg	960
cggtggctgt	ttatctgaga	acctttaagg	cgtctgagat	atggcttttc	ctgatagcgg	1020
ttatggggcgt	gtttttttatg	atcttccgcc	gttatctgga	cagtatttca	aaatattttta	1080
aggagatcaa	ccgggggatc	gatacttttg	tgaatgagga	tgccaacgat	attgggctgc	1140
ctccggagtt	ggcttcgacc	gaaagaaaaa	tcaattccat	acggcatacc	ctgacgaaac	1200
ggaaaacgga	cgctgagctt	gcagagcaaa	ggaaaaacga	tcttgtcatg	tatctggccc	1260
atgacctgaa	gaccccgctt	ccatcggtca	taggatattt	gaacctgtta	agggatgaga	1320
atcagatttc	cgaggaactt	agggaaaaat	atttgtccat	atcattggat	aaggctgagc	1380
gtctggaaga	actgattaat	gagttttttg	aaattacgag	gtttaatctt	tcaaacaatca	1440
cgcttggtga	cagcaaaatc	aatctgacga	tgatctgga	acagctgggg	tatgagttta	1500
agccgatgct	ggccgggaaa	aatctgaaat	gtgaatttga	tgttcagcca	gacatgatgc	1560
tgtcctgcga	tgccaacaag	ctgcagcggg	tcttcgataa	tgtgctgaga	aatgccgtca	1620

-8-

gctactgcta	tgagaataacc	accatttcggg	tgaagccag	gcagaccgaa	gaccatgtac	1680
tcatcaaaat	cataaacgaa	ggggatacga	ttcctgggga	gagattggaa	agaatctttg	1740
agcagtttta	ccgcctggat	gtatctcgaa	gctcaagtac	cggcggggcc	ggctctggggc	1800
ttgccattgc	aaaagagatt	gtggaactgc	accatggaca	gatcactgcc	cacagcgaaa	1860
atggtatcac	cagttttgag	gttacattgc	ccgtcgtagg	aaaatcgtaa	gaaattccga	1920
gataaacctg	gtgttatcca	taaaagaacg	cgaaaacata	aatcgctcta	ttctggtatg	1980
ctttatatca	ggagggggcga	tttttttgct	ttcagaaagg	agttcagggg	aatgatggaa	2040
tatcaaaaca	ataatggaaa	ctatgacaaa	aggaatcgta	gaaaagccaa	aaaaagaaaa	2100
ttgctttttt	acaggggtgc	atgtgtcaca	ctttgtttgc	tcattgtttc	tgtaatcttt	2160
ggagttgtgc	attttttagg	ggagagtaaa	gatcccgccc	ttttatccaa	agaaaacaca	2220
aaaacagaca	agaactattc	gtggcttacc	gacgatcaga	atgaggcagt	accctcagtt	2280
ccagagccag	ccatatccga	ccaggctaac	aaaatttcgg	taaatatcac	agcggcaaac	2340
gccattgtaa	tgaataaaga	cacaaatgag	gtattgtacc	agaaaaaaag	cacagccaaa	2400
attgcgccgg	ccagcactgc	taagatgatt	atggccttga	cagcacttga	ctattgttcc	2460
ccggaggatg	aaatgaaagt	aggtgcggag	attggaatga	ttcaaagcga	ttcgtcaacc	2520
gcatggctta	tgaagggtga	tacactgact	gtcagacagc	tcctgattgc	ccttatgctt	2580
ccgtccggca	atgatgcagc	ctataccctt	gcagtcaata	ccggaaaggc	tattgcagggt	2640
gataacagcc	tgaccagtca	gcaagcgatt	gaagtattca	tggataaggt	aaatgaaaaa	2700
gccgtggccc	ttggcgccac	aaactcgaaa	tttgtagctc	cggatggata	tgatgccgaa	2760
gggcagtata	ctacagctta	tgaccttgct	atcattgcaa	aagcatgttt	ggacaatcct	2820
atcatttcgg	agattgtagc	gagttattca	tcctatgaaa	aatggtcaaa	cggaagagag	2880
gtcacttaca	acaattccaa	tgagcttctc	gatccgaaca	gtccctatta	ccgtccggag	2940
gttatcggtt	tgaaaacagg	aaccagcagt	cttggcggcg	catgtattgt	ttctgcagcg	3000
gtgatggacg	gagaaaacct	tatctgtgta	gttatgggtt	ctacaaagga	aagcagggtt	3060
caggacagcg	ttgatatttt	agataaaatc	aaagcccagt	aacgaagata	ggaggaaatg	3120
aatggagaaa	ataatagaca	taactgtttt	tggctgcgag	ccagacgaaa	tggagggttt	3180
tcaaaagatt	tcttatgagc	ttgggtgttc	agccacactc	ataaaagatt	ctatatcaga	3240
aagcaatgct	ggattagcta	atggatgccg	gtgtgttaag	gtaagccata	aagcggagct	3300
atcagaaccg	attcttcttg	cgctaaaaaa	tgcaggggta	aaatatatca	gtacccggag	3360
cattggtttt	aaccatattg	atatacaggc	ggctgggtta	ctgggtatgg	ttgttggcac	3420
agtagaatac	tcgcccggaa	gtgtggccga	ttataccgtc	atgctgatgc	ttatgctgat	3480
gcgtggcaca	aagtcgattc	tgctgaaac	ccagaggcag	aattattgcc	tgaatgacct	3540
gcgcggaaaa	gaactgcggg	atatgaccgt	gggtgtgtta	ggaactgggc	gaatcggaca	3600
ggcagtcattg	gagcgcctgg	agggattcgg	ttgtaaggta	ttggcgctatg	accgaaatca	3660
aaaagcagga	gcagactatg	tttcgtttca	tgaactgctg	aaaaaaagtg	acattgttac	3720
actgcatatc	ccgttggcgg	aggatacccg	ccatatgatt	ggctatgaag	agctggaaat	3780
gatgaaggaa	gaggcgcttc	tgatcaatac	agggcggggc	gcttttagtgg	gtaccgcagc	3840
attggtagaa	gcattaaaag	gacagaaaat	cgccggcgcc	ctggatgttt	tggaaaggcga	3900
agaaggatc	ttttaccatg	actgcaccca	aagaagaata	gaacatcctt	tcctgtcggt	3960
cctgcaggga	atgccgaatg	tcattgttac	gccgcacaca	gcctatcata	cggaaacgggt	4020
gttggttgac	acggtcagaa	atactattag	aaattgtttg	aattttgaaa	ggagtctggg	4080
aaatgttttag	aattaaagtt	gcagttctgt	ttgggggctg	ttcagaggaa	cataatgttt	4140
cgataaaatc	tgcatggag	attgccgcaa	acatagatac	aaaaaaatat	cagccttatt	4200
atattggaat	cacaaaatcc	ggcgttttga	aaatgtgtga	aaaaccttgt	ttggagtggtg	4260
aacaatatgc	gggggatccg	gttgtttttt	cgccggacag	aagtacgcac	ggtctgctga	4320
tacaaaaaga	caaagggtat	gaaatccagc	ctgtggatgt	ggtgtttccg	atgattcatg	4380
gcaagtttgg	ggaggatggc	tccatacaag	gcttgcttga	attgtcaggc	attccgtatg	4440
tgggatgcga	tattcaaagc	tccgtgatct	gcatggataa	ggcgcttgca	tataccgttg	4500
tgaaaaatgc	gggtatcact	gtgcctgggt	tccggatcct	tcaggagggg	gatcgcttgg	4560
aaacggagga	tttcgtatat	cccgtttttg	taaagcctgc	ccgttccggc	tcatcctttg	4620
gcgtaaacaa	ggtatgcaag	gcagaagaac	tgcaggcagc	aatcgaagaa	gcaagaaaat	4680
atgacagcaa	gattttgatt	gaagaggccg	ttaccgggag	tgaggtaggc	tgcgccatac	4740
tgggaaacgg	aaatgatctc	atggctggcg	aggtggatca	gattgagctg	agacacggct	4800
tttttaagat	tcatcaggaa	gcacagccgg	agaagggtac	tgaaaaatgca	gtcatccgag	4860
ttccagccgc	cttaccggat	gaggtaagag	aacagattca	ggaaacggca	atgaagattt	4920
accggatact	tggctgcaga	ggattggccc	gcattgacct	gtttttgcgg	gaggacgggt	4980
gcattgtgct	gaatgaagtg	aataccatgc	caggttttac	ttcctacagc	cgctatcccc	5040

-9-

gcatgatgac	agcagccggt	tttacgcttt	ctgaaatact	ggatcgcttg	attgaacttt	5100
cacttaggag	gtaactgtca	tgaaaaagaa	ctttgccttt	ttagatgaaa	tgattcccgg	5160
gatccgatgg	gatgccaaat	atgccacctg	ggacaatttc	accgggaaac	cggtagacgg	5220
atacatggta	aaccgtgtta	tgggaacgaa	ggagctggga	gttgctttgc	gtaaggctca	5280
gaagatggcg	gagaagctag	gatatggttt	gctcttatgg	gacggctatc	gccccagtg	5340
cgcagtgaat	tgttttctga	attgggcttc	ccaaccggaa	gacaatctga	cgaaaaagcg	5400
ttactatcca	aatatcaaaa	ggaatgagat	ggttgcgaag	gggtatgtgg	cctcacaatc	5460
cagccacagc	cgtggaagta	cggttgacct	tacaattttt	catttgaata	gcggtatgct	5520
tgttcctatg	ggtggagatt	ttgactttat	ggatgaacgg	tcacaccatg	ccgcaagcgg	5580
tctgagcgaa	gaagaatcaa	aaaaccggca	gtgcttgctg	tatatcatgg	agagtagcgg	5640
atttgaagcc	tatcgttatg	aatggtggca	ttacgtcttg	gcggacgagc	catacccgga	5700
tacatatattt	gatttttgca	ttgcctagtg	agagcctgaa	gaaatgaaaa	atgtaagatt	5760
ataaggacaa	gcggcatgag	g				5781

<210> 5
 <211> 27
 <212> DNA
 <213> Enterococcus faecium

<400> 5
 ggtggcgcgg gacttggatg gcgattg 27

<210> 6
 <211> 30
 <212> DNA
 <213> Enterococcus faecium

<400> 6
 ggcgcggatg attatataac gaagcccttt 30

<210> 7
 <211> 18
 <212> DNA
 <213> Enterococcus faecium

<400> 7
 cgagccggaa aaaggctc 18

<210> 8
 <211> 20
 <212> DNA
 <213> Enterococcus faecium

<400> 8
 ggctgcgata ttcaaagctc 20

<210> 9
 <211> 27
 <212> DNA
 <213> Enterococcus faecium

<400> 9
 attactgttt atggatgtga gcaggat 27

<210> 10

-10-

<211> 26
<212> DNA
<213> Enterococcus faecium

<400> 10
gtggcttcaa aatcaagcca tagccg 26

<210> 11
<211> 18
<212> DNA
<213> Enterococcus casseliflavus

<400> 11
cgagccggaa aaaggctc 18

<210> 12
<211> 20
<212> DNA
<213> Enterococcus casseliflavus

<400> 12
ggctgcgata ttcaaagctc 20

<210> 13
<211> 20
<212> DNA
<213> Enterococcus faecium

<400> 13
ggctgcgata ttcaaagctc 20

<210> 14
<211> 30
<212> DNA
<213> Enterococcus faecium

<400> 14
cuacuacuac uacgaattca agaacactgg 30

<210> 15
<211> 36
<212> DNA
<213> Enterococcus faecium

<400> 15
caucauac auccaaccct ttctgtgaaa ggcacc 36

<210> 16
<211> 38
<212> DNA
<213> Enterococcus faecium

<400> 16
cuacuacuac uactcgaggc ttatcacccc tttaacgc 38

<210> 17
<211> 32

-11-

<212> DNA

<213> Enterococcus faecium

<400> 17

caucaucauc auggagacag gagcatgaat ag

32

<210> 18

<211> 696

<212> DNA

<213> Enterococcus faecium

<400> 18

atgagcgata	aaatacttat	tgtggatgat	gaacatgaaa	ttgccgattt	ggttgaatta	60
tacttaaaaa	acgagaatta	tacgggttttc	aaatactata	ccgccaaaga	agcattggaa	120
tgtatagaca	agtctgagat	tgaccttgcc	atattggaca	tcatgcttcc	cggcacaagc	180
ggccttacta	tctgtcaaaa	aataagggac	aagcacacct	atccgattat	catgctgacc	240
gggaaagata	cagaggtaga	taaaattaca	gggttaacaa	tcggcgcgga	tgattatata	300
acgaagccct	ttcgccact	ggagttaatt	gctcgggtaa	aggcccagtt	gcgccgatac	360
aaaaaaattca	gtggagtaaa	ggagcagaac	gaaaatgtta	tcgtccactc	cggccttgtc	420
attaatgtta	acacccatga	gtgttatctg	aacgagaagc	agttatccct	tactcccacc	480
gagttttcaa	tactgcgaat	cctctgtgaa	aacaagggga	atgtgggttag	ctccgagctg	540
ctatttcatg	agatatgggg	cgacgaatat	ttcagcaaga	gcaacaacac	catcaccgtg	600
catatccggc	atttgcgga	aaaaatgaac	gacaccattg	ataatccgaa	atatataaaa	660
acggtatggg	gggttggtta	taaaattgaa	aaataa			696

<210> 19

<211> 1155

<212> DNA

<213> Enterococcus faecium

<400> 19

ttggttataa	aattgaaaaa	taaaaaaaac	gactattcca	aactagaacg	aaaactttac	60
atgtatatcg	ttgcaattgt	tgtggtagca	attgtattcg	tggtgtatat	tcgttcaatg	120
atccgaggga	aacttgggga	ttggatctta	agtatttttg	aaaacaaata	tgacttaaat	180
cacctggacg	cgatgaaatt	atatcaatat	tccatacggg	acaatataga	tatctttatt	240
tatgtggcga	ttgtcattag	tattcttatt	ctatgtcgcg	tcatgctttc	aaaattcgca	300
aaatactttg	acgagataaa	taccggcatt	gatgtactta	ttcagaacga	agataaaaca	360
attgagcttt	ctgcggaaat	ggatgttatg	gaacaaaagc	tcaacacatt	aaaacggact	420
ctggaaaagc	gagagcagga	tgcaaagctg	gccgaacaaa	gaaaaaatga	cgttgttatg	480
tacttggcgc	acgatattaa	aacgcccctt	acatccatta	tcgggttattt	gagcctgctt	540
gacgaggctc	cagacatgcc	ggtagatcaa	aaggcaaaag	atgtgcatat	cacgttggac	600
aaagcgtatc	gactcgaaca	gctaatcgac	gagttttttg	agattacacg	gtataaccta	660
caaacgataa	cgctaacaaa	aacgcacata	gacctatact	atatgctggt	gcagatgacc	720
gatgaatttt	atcctcagct	ttccgcacat	ggaaaacagg	cggttattca	cgccccgag	780
gatctgaccg	tgtccggcga	ccctgataaa	ctcgcgagag	tctttaacaa	cattttgaaa	840
aacgcgcgtg	catacagtga	ggataacagc	atcattgaca	ttaccgcggg	cctctccggg	900
gatgtggtgt	caatcgaatt	caagaacact	ggaagcatcc	caaaagataa	gctagctgcc	960
atatttgaaa	agttctatag	gctggacaat	gctcgttctt	ccgatacggg	tggcgcggga	1020
cttggtattg	cgattgcaaa	agaaattatt	gttcagcatg	gagggcagat	ttacgcggaa	1080
agcaatgata	actatacgac	gtttagggta	gagcttccag	cgatgccaga	cttggttgat	1140
aaaaggaggt	cctaa					1155

<210> 20

<211> 969

<212> DNA

<213> Enterococcus faecium

-12-

<400> 20

atgaataaca	tcggcattac	tgtttatgga	tgtgagcagg	atgaggcaga	tgcatcccat	60
gctctttcgc	ctcgctttgg	cgttatggca	acgataatta	acgccaacgt	gtcgggaatcc	120
aacgccaaat	ccgcgccttt	caatcaatgt	atcagtgtgg	gacataaatc	agagatttcc	180
gcctctattc	ttcttgcgct	gaagagagcc	gggtgtgaaat	atatttctac	ccgaagcatc	240
ggctgcaatc	atatagatac	aactgctgct	aagagaatgg	gcactactgt	cgacaatgtg	300
gcgtactcgc	cggatagcgt	tgccgattat	actatgatgc	taattcttat	ggcagtagcg	360
aacgtaaaat	cgattgtgcg	ctctgtggaa	aaacatgatt	tcaggttggg	cagcgaccgt	420
ggcaaggtag	tcagcgacat	gacagttggg	gtgggtgggaa	cgggccagat	aggcaaagcg	480
gttattgagc	ggctgcgagg	atttggatgt	aaagtgttgg	cttatagtcg	cagccgaagt	540
atagaggtaa	actatgtacc	gtttgatgag	ttgctgcaaa	atagcgatat	cgttacgctt	600
catgtgccgc	tcaatacggg	tacgcactat	attatcagcc	acgaacaaat	acagagaatg	660
aagcaaggag	catttcttat	caatactggg	cgcggctccac	ttgtagatac	ctatgagttg	720
gttaaagcat	tagaaaacgg	gaaactgggc	gggtgccgcat	tggatgtatt	ggaaggagag	780
gaagagtttt	tctactctga	ttgcacccaa	aaaccaattg	ataatcaatt	tttacttaaa	840
cttcaaagaa	tgccaaacgt	gataatcaca	ccgcatacgg	cctattatac	cgagcaagcg	900
ttgcgtgata	ccgttgaaaa	aaccattaaa	aactgtttgg	attttgaaa	gagacaggag	960
catgaatag						969

<210> 21

<211> 1032

<212> DNA

<213> Enterococcus faecium

<400> 21

atgaatagaa	taaaagttgc	aatactgttt	gggggttgct	cagaggagca	tgacgtatcg	60
gtaaaatctg	caatagagat	agccgctaac	attaataaag	aaaaatacga	gccgttatac	120
a :tggaatta	cgaaatctgg	tgtatggaaa	atgtgcgaaa	aaccttgccg	ggaatgggaa	180
aacgacaatt	gctattcagc	tgtactctcg	ccggataaaa	aaatgcacgg	attacttggt	240
aaaaagaacc	atgaatatga	aatcaaccat	gttgatgtag	cattttcagc	tttgcattgg	300
aagtcagggt	aagatggatc	catacaaggt	ctgtttgaat	tgcccggtat	cccttttgta	360
ggctgcgata	ttcaaagctc	agcaatttgt	atggacaaaat	cgttgacata	catcgttgcg	420
aaaaatgctg	ggatagctac	tcccgccttt	tgggttatta	ataaagatga	taggccgggt	480
gcagctacgt	ttacctatcc	tgtttttgtt	aagccggcgc	gttcaggctc	atccttcggt	540
gtgaaaaaag	tcaatagcgc	ggacgaattg	gactacgcaa	ttgaatcggc	aagacaatat	600
gacagcaaaa	tcttaattga	gcaggctgtt	tcgggctgtg	aggtcgggtg	tgcgggtattg	660
ggaaacagtg	ccgcgttagt	tgttggcgag	gtggacaaaa	tcaggctgca	gtacgggaatc	720
tttcgtattc	atcaggaagt	cgagccggaa	aaaggctctg	aaaacgcagt	tataaccggt	780
cccgcagacc	tttcagcaga	ggagcgagga	cggatacagg	aaacggcaaa	aaaaatatat	840
aaagcgctcg	gctgtagagg	tctagcccgt	gtggatatgt	ttttacaaga	taacggccgc	900
attgtactga	acgaagtcaa	tactctgccc	ggtttcacgt	catacagtcg	ttatccccgt	960
atgatggccg	ctgcagggtat	tgcacttccc	gaactgattg	accgcttgat	cgtatttagcg	1020
ttaaaggggt	ga					1032

<210> 22

<211> 609

<212> DNA

<213> Enterococcus faecium

<400> 22

atggaaatag	gatttacttt	tttagatgaa	atagtacacg	gtgttcggtg	ggacgctaaa	60
tatgccactt	gggataattt	caccggaaaa	ccgggtgacg	gttatgaagt	aaatcgcatt	120
gtagggacat	cagagttggc	tgaatcgctt	ttgaaggcaa	aagaactggc	tgctacccaa	180
gggtacggat	tgcttctatg	ggacggttac	cgctctaagc	gtgctgtaaa	ctgttttatg	240
caatgggctg	cacagccgga	aaataacctg	acaaaggaaa	gttattatcc	caatattgac	300
cgaactgaga	tgatttcaaa	aggatacgtg	gcttcaaaat	caagccatag	ccgcggcagt	360
gccattgatc	ttacgccttta	tcgattagac	acgggtgagc	ttgtaccaat	ggggagccga	420

-13-

tttgatttta	tggatgaacg	ctctcatcat	gcggaacatg	gaatatcatg	caatgaagcg	480
caaaatcgca	gacgtttgcg	ctccatcatg	gaaaacagtg	ggtttgaagc	atatagcctc	540
gaatggtggc	actatgtatt	aagagacgaa	ccatacccca	atagctattt	tgatttcccc	600
gttaaataa						609

<210> 23

<211> 912

<212> DNA

<213> Enterococcus faecium

<400> 23

atgaagaagt	tggttttttt	attgttattg	ttattcctaa	tatacttagg	ttatgactac	60
gttaaatgaag	cactgttttc	tcaggaaaaa	gtcgaatttc	aaaattatga	tcaaaatccc	120
aaagaacatt	tagaaaatag	tgggacttct	gaaaataccc	aagagaaaac	aattacagaa	180
gaacagggtt	atcaaggaaa	tctgctatta	atcaatagta	aatatcctgt	tcgccaagaa	240
agtgtgaagt	cagatatcgt	gaatttatct	aaacatgacg	aattaataaa	tggatacggg	300
ttgcttgata	gtaatattta	tatgtcaaaa	gaaatagcac	aaaaattttc	agagatggtc	360
aatgatgctg	taaaggggtg	cgttagtcac	tttattatta	atagtggcta	tcgagacttt	420
gatgagcaaa	gtgtgcttta	ccaagaaatg	ggggctgagt	atgccttacc	agcagggttat	480
agtgagcata	attcagggtt	atcactagat	gtaggatcaa	gcttgacgaa	aatggaacga	540
gccccgaag	gaaagtggat	agaagaaaat	gcttggaat	acgggttcac	tttacgttat	600
ccagaggaca	aaacagagtt	aacaggaatt	caatatgaac	catggcatat	tcgctatggt	660
ggtttaccac	atagtgcgat	tatgaaagaa	aagaatttcg	ttctcgagga	atatatggat	720
tacctaaaag	aagaaaaaac	catttctgtt	agtgtaaatg	gggaaaaata	tgagatcttt	780
tattatcctg	ttactaaaaa	taccaccatt	catgtgccga	ctaactctcg	ttatgagata	840
tcaggaaaca	atatagacgg	tgtaattgtg	acagtgtttc	ccggatcaac	acatactaat	900
tcaaggaggt	aa					912

<210> 24

<211> 486

<212> DNA

<213> Enterococcus faecium

<400> 24

ttgggaaaaa	tattatctag	aggattgcta	gctttatatt	tagtgacact	aatctgggta	60
gtgttattca	aattacaata	caatatttta	tcagtattta	attatcatca	aagaagtctt	120
aacttgactc	catttactgc	tactgggaat	ttcagagaga	tgatagataa	tgttataatc	180
tttattccat	ttggcttgct	tttgaatgtc	aattttaaag	aaatcggatt	tttacctaag	240
tttgcttttg	tactggtttt	aagtcttact	tttgaaataa	ttcaatttat	cttcgctatt	300
ggagcgacag	acataacaga	tgtaattaca	aatactgttg	gaggctttct	tggactgaaa	360
ttatatgggt	taagcaataa	gcatatgaat	caaaaaaat	tagacagagt	tattattttt	420
gtaggtatac	ttttgctcgt	attattgctc	gtttaccgta	cccatttaag	aataaattac	480
gtgtaa						486

<210> 25

<211> 19

<212> DNA

<213> Enterococcus faecium

<400> 25

cgaataccgc	aagcgacag	19
------------	-----------	----

<210> 26

<211> 663

<212> DNA

<213> Enterococcus faecium

-14-

<400> 26

atgtcgatac	gaattctact	tgtcgaggat	gatgatcata	tctgcaatac	agtaagggcg	60
tttttggtcg	aagcaagata	tgagggtgat	gcctgcacag	atggaaacga	agcacacacc	120
aagttctatg	aaaacaccta	tcaactgggt	attcttgata	ttatgctgcc	cggtatgaat	180
gggcatgaac	ttctacgtga	atttcgggcg	caaaatgata	ccccattct	gatgatgaca	240
gccctgtcgg	atgacgaaaa	ccaaatccgg	gcgtttgatg	cagaggcaga	cgactatgta	300
acaaagccat	tcaagatgcg	gattttacta	aagcgggtgg	aagccctgtt	acggcgcagc	360
ggtgcgctgg	caaaggaatt	tcgtgtgggc	aggctgacac	ttctgccgga	ggatttttagg	420
gtactttgtg	acggtacgga	gctgccccctg	acacgaaaag	aatttgaaat	ccttttgctg	480
ctgggtgcaga	acaaaggcag	aaccttaacc	catgaaatca	ttttgtcccc	catatgggga	540
tatgactttg	acggtgatgg	cagcacagtc	cacatcata	tcaaaaatct	gcgggcgaag	600
ctgccgga	atatcatcaa	aaccatccgc	ggtgtagggt	accgattgga	ggaatcatta	660
taa						663

<210> 27

<211> 1344

<212> DNA

<213> *Enterococcus faecium*

<400> 27

atggaaagaa	aagggtttt	cattaagggt	ttttcctata	cgatcattgt	cctgttactg	60
cttgctgggtg	taacggcaac	actgtttgca	cagcaatttg	tgtcttattt	cagagcgatg	120
gaagcacagc	aaacagtaaa	atcctatcag	ccattgggtg	aactgattca	gaatagcgat	180
aggcttgata	tgcaagaggt	ggcagggctg	tttccactaca	ataaccaatc	ctttgagttt	240
tatattgaag	ataaagaggg	aagcgtactc	tatgccacac	cgaatgccga	tacatcaaat	300
agtgttaggc	ccgactttct	ttatgtggta	catagagatg	ataatatttc	gattgttgct	360
caaagcaagg	caggtgtggg	attgctttat	caagggctga	caattcgggg	aattgttatg	420
attgc ,ataa	tggttgatt	cagcctttta	tgcgcgata	tctttgcgcg	gcaaatagaca	480
acgccgatca	aagccttagc	ggacagtgcg	aataaaatgg	caaacctgaa	agaagtaccg	540
ccgccgctgg	agcgaagga	tgagcttggc	gcactggctc	acgacatgca	ttccatgtat	600
atcaggctga	aagaaaccat	cgcaaggctg	gaggatgaaa	tcgcaaggga	acatgagttg	660
gaggaaacac	agcgatattt	ctttgcggca	gcctctcatg	agttaaaaac	gcccacgcg	720
gctgtaagcg	ttctgttgga	gggaatgctt	gaaaatatcg	gtgactacaa	agaccattct	780
aagtatctgc	gcgaatgcat	caaaatgatg	gacaggcagg	gcaaaaccat	ttccgaaata	840
ctggagcttg	tcagcctgaa	cgatgggaga	atcgtaccca	tagccgaacc	gctggacata	900
gggcgcacgg	ttgccgagct	gctacccgat	tttcaaacct	tggcagaggc	aaacaaccag	960
cggttcgtca	cagatattcc	agccggacaa	attgtcctgt	ccgatccgaa	gctgatccaa	1020
aaggcgctat	ccaatgtcat	attgaatgcg	gttcagaaca	cgccccaggg	aggtgaggta	1080
cggatatgga	gtgagcctgg	ggctgaaaaa	taccgtcttt	ccgttttgaa	catgggcggt	1140
cacattgatg	atactgcact	ttcaaagctg	ttcatcccat	tctatcgcat	tgatcaggcg	1200
cgaagcagaa	aaagtgggcg	aagcggtttg	gggcttgcca	tcgtacaaaa	aacgctggat	1260
gccatgagcc	tccaatatgc	gctggaaaaac	acctcagatg	gcgttttgtt	ctggctggat	1320
ttaccgcca	catcaacact	ataa				1344

<210> 28

<211> 807

<212> DNA

<213> *Enterococcus faecium*

<400> 28

atggaaaaaa	gcaactatca	ttccaatgtg	aatcatcaca	aacggcatat	gaaacaatct	60
ggggaaaaaa	gggcttttct	atgggcgttc	attatctcgt	tcacagtctg	cacgctgttt	120
ttgggggtgga	gattggtttc	cgtattggag	gcaacacagc	taccgcccac	ccctgcaact	180
catacaggca	gcgggactgg	tgtagcggag	aatccagagg	aaaacactct	tgcccacgcc	240
aaagaacagg	gagatgaaca	ggaatggagc	ctgatttttag	tgaacaggca	gaaccccatc	300
cccggccagt	acgatgtgga	acttgagcag	ctgtcaaatg	gtgagcggat	agacattcgg	360
atctctccct	acctccagga	tttgtttgat	gccgcaagag	ctgatggagt	ttacccgatt	420

-15-

gtcgcacccg	gataccggac	aacagaaaaa	cagcaagaaa	tcacggatga	aaaagtcgcc	480
gaatacaagg	cgaaaggcta	cacctctgca	caggctaaaag	cggaagcaga	aacttgggtg	540
gccgtgccgg	gaacaagcga	gcatcagctt	ggctcttgctg	tggaatataa	tcgggatgga	600
attcattcaa	ccggcaacga	ggttttacaga	tggttgatg	aaaacagcta	tcgctttggt	660
tttattcgcc	gctacccgcc	agacaagaca	gagataaccg	gtgtgagcaa	cgagccgtgg	720
cattaccgat	atgtcggcat	cgaagctgcc	acaaagatat	accaccaagg	gctttgcctt	780
gaggaatatt	taaacacaga	aaaatga				807

<210> 29

<211> 972

<212> DNA

<213> Enterococcus faecium

<400> 29

atgagaaaaa	gtatgggcat	tactgttttt	ggatgcgagc	aggatgagggc	aaatgctttc	60
cgcaccttat	caccagattt	tcataattatc	cctacgctga	tcagtgatgc	gatatcggca	120
gacaacgcaa	aattggccgc	tggaatcaa	tgcattagcg	taggccataa	gtccgagggt	180
tccgaggcga	caattcttgc	gctgagaaaag	gtcggggtaa	aatacatttc	taccgcgagc	240
atcggctgca	atcacattga	tacgactgcc	gccgagagaa	tggggatctc	ggttggcaca	300
gttgcgctatt	cgccggacag	cggtgcggat	tatgctttga	tgctgatgct	gatggccata	360
cggggtgcaa	agtcacccat	acacgccgtg	gcgcaacaaa	atttcagact	ggattgtgtc	420
cgggggaaaag	agctgcggga	tatgactgtg	ggagttattg	gaaccggcca	tatagggcaa	480
gcggtcgta	aaaggctgcg	gggatttgga	tgccgtgtgc	tagcctatga	taacagccga	540
aaaattgagg	cagattatgt	ccagcttgat	gagcttctaa	aaaacagcga	tattgttacg	600
ctccatgtgc	cgctttgtgc	ggataccgcg	catctgatcg	gccagagcga	aatcggagag	660
atgaagcaag	gcgcattttt	aatcaacact	ggcgcggggg	cgcttgctga	taccgggtcg	720
ctggtggagg	cactgggaag	cggaaagctg	ggcggtgcgg	cactggatgt	gttggagggc	780
gaggatcagt	ttgtttatac	cgactgctcg	cagaaagtgc	ttgaccatcc	ctttttgtcg	840
cagctcctaa	ggatgccaaa	tgtgatcatc	acaccccata	cggcgacta	caccgagcgt	900
gtgctgcgag	ataccacaga	aaaaacaatc	aggaattgtc	ttaactttga	aaggagttaa	960
cagcatgaat	aa					972

<210> 30

<211> 1029

<212> DNA

<213> Enterococcus faecium

<400> 30

atgaataaaa	taaaagtcgc	aattatcttc	ggcggttgct	cggaggaaca	tgatgtgtcg	60
gtaaaatccg	caatagaaat	tgctgcgaac	attaatactg	aaaaattcga	tccgcactac	120
atcggaatta	caaaaaacgg	cgtatggaag	ctatgcaaga	agccatgtac	ggaatgggaa	180
gccgatagtc	tccccgccat	attctccccg	gataggaaaa	cgcatggctc	gcttgtcatg	240
aaagaaaagag	aatacgaaac	tcggcgctatt	gacgtggctt	tcccggtttt	gcatggcaaa	300
tgccggggagg	atggcgcat	acagggtctg	tttgaattgt	ctgggtatccc	ctatgtaggg	360
tgcatatttc	aaagctccgc	agcttgcatg	gacaaatcac	tgccctacat	tcttcaaaaa	420
aatgcgggca	tcgccgtccc	cgaatttcaa	atgattgaaa	aagggtgaaa	accggaggcg	480
aggacgctta	cctaccctgt	ctttgtgaag	ccggcacggg	cagggttcgtc	ctttggcgta	540
accaaagtaa	acagtacgga	agaactaaac	gctgcgatag	aagcagcagg	acaatatgat	600
ggaaaaatct	taattgagca	agcgatttgc	ggctgtgagg	tcggctgcgc	ggcatgggga	660
aacgaggatg	atttgattgt	cggcgaaagt	gatcaaatcc	ggttgagcca	cggatctctc	720
cgcattccatc	aggaaaacga	gccggaaaaa	ggctcagaga	atgcgatgat	tatcgttcca	780
gcagacattc	cggtcgagga	acgaaatcgg	gtgcaagaaa	cggcaaagaa	agtatatcgg	840
gtgcttgatg	gcagagggct	tgctcgtgtt	gatctttttt	tgcaaggagg	tgccggcatc	900
gttctaaacg	aggtcaatac	cctgcccggg	tttacatcgt	acagccgcta	tccacgcgat	960
gcggctgcgg	caggaatcac	gcttcccgcg	ctaattgaca	gcctgattac	attggcgata	1020
gagaggtga						1029

-16-

<210> 31
 <211> 609
 <212> DNA
 <213> *Enterococcus faecium*

<400> 31
 atggaaaatg gttttttgtt tttagatgaa atgttgcatt gtgttcgttg ggatgccaaag 60
 tacgctacat gggataaact cacgggaaaa ccagtggatg ggtatgaggt gaatcgcatc 120
 atcggcacaa aggccgtggc gcttgctctg cgcgaagcac aaatccatgc ggcacgcctt 180
 ggctacggct tgcttttatg ggatggatat cggccaaaat ctgcggtgga ctgtttcctg 240
 cgttgggagg cgcagccgga ggacaacctc acaaaagaaa aatattaccc caatattgag 300
 cgagccgagt tgattacaaa gggctatgtg gcctcacaat ccagccatag ccgtggaagc 360
 acaattgac ttacgctcta ccacttggat acaggggaac ttgtttcaat gggaagcaac 420
 ttcgatttta tggacgaacg gtcgcacccat acagcaaaag ggatagggaa tgcagaggca 480
 caaaatcgaa gatgcttgcg taaaatcatg gaaagcagcg gatttcagtc ctatcgcttt 540
 gaatgggtggc actataagtt gattgatgag ccataccccg atacctattt taattttgct 600
 gtttcataa 609

<210> 32
 <211> 828
 <212> DNA
 <213> *Enterococcus faecium*

<400> 32
 atgaacagaa aaagattgac acagcgcttc ccgttcctgc ttccaatgag acaagcgcag 60
 agaaaaatat gcttttatgc gggaaatgaga tttgacggct gttgctatgc acagacgata 120
 ggagaaaaaa cgcttcctta tttgctcttt gaaacggatg gtgcgttata caaccacaat 180
 accggatttg acatgatata ccaagaaaaac aagggtgttca acttaaagct ggcggcaaaag 240
 accttaaacy gcctattgat aaaaccgggg gaaacctttt ctttctggcg gctggtacgc 300
 catgcggaaca aagatacccc ctataaagac ggccttacgg tggccaatgg taagctcacc 360
 accatgtcgg gcggcggtat gtgccagatg agcaatttac tattttgggt gttcctgcac 420
 acgccattga caattatcca gcgcagcggt cacgtagtaa aggagtttcc agagccaaac 480
 agtgacgaga tcaaaggggt ggatgcaacc atctcagagg gctggattga tttaaaagtg 540
 cgaaacgata ccgactgcac ctaccaaata tgggtgaccc tagatgatga gaaaatcatc 600
 ggtcaggtgt tcgccgacaa acagcctcaa gcattataca aaattgcaaa cggcagttat 660
 cagtatgtcc gtgaaagtgg cgggatttat gaatatgcca aggttgaacg gatgcaagtt 720
 gccttaggta ccgggggaaat aatagattgc aagctgcttt atacaaacaa atgcaaaatc 780
 tgctatcccc tcccggaaag tgtggatatt caggaggcga accaatga 828

<210> 33
 <211> 1053
 <212> DNA
 <213> *Enterococcus casseliflavus*

<400> 33
 atgaaaaaaa tcgccattat ttttggaggc aattcacccg aatacacccg ttcttttagct 60
 tcagcaacta gcgcaatcga agcactccaa tcactctccct atgactacga cctctctttg 120
 atcgggatcg cccagatgc tatggattgg tacttgata caggagaact ggaaaacatc 180
 cgacaagaca cgtgggtgtt ggatacgaaa cataaacaga aaatacagcc gctattcgaa 240
 ggaaacggct tttggctaag tgaagagcag caaacggttg tacctgatgt tttatttccc 300
 attatgcatg gcaaatacgg ggaagatggc agtatccaag gattgtttga attgatgaag 360
 ctgccttatg taggctgcgg ggtggcaggt tctgccttat gtatgaacaa atggctgctg 420
 catcaagctg cagcagccat tggcgtaaaa agtgctccta cgattctctt gacaaatcaa 480
 gccaacagc aagaacaaat cgaagctttt atccagaccc atggcttccc agttttcttt 540
 aagcctaagt aagcgggctc ctcaaaagg atcactaaag tcacctgcgt tgaagaaatc 600
 gcttctgcct taaaagaagc ctttacttat tgttccgcag tgctcctaca aaaaaatatt 660
 gccgggtgtg agatcggttg cggatttttg ggcaacgact ctttgactgt cgggtgcttg 720

-17-

gacgccat	ttt cattag	taga cggct	tttttc gatttt	gaag aaaag	tacca gctgat	cagc 780
gccaaaa	tca ccgtc	ccctgc gccatt	gcct gaaac	gattg aaacca	aggc caaaga	aacaa 840
gctcagc	tgc tctat	cgtag tcttg	gtctt aaagg	tcttg ctcgc	atcga cttttt	gttc 900
acggagc	gag gaga	aactata cttga	atgaa atca	aacta tgccg	gggtt tacga	gtcac 960
tcccgtc	atc ctgcc	atgat ggcag	cgggtc ggctt	atcct atca	agaact acta	caaaaa 1020
ctgcttg	tct tagc	aaagga ggaag	tcaaa tga 1053			

<210> 34

<211> 699

<212> DNA

<213> Enterococcus faecium

<400> 34

atgaatg	aaa aaatc	ttagt ggttg	atgat gaaaa	agaat tggcc	gactt agttg	aagta 60
tatctga	aaaa acgat	ggata taccg	tttat aaatt	tttata atggc	aagga tgcact	aaag 120
tgtattg	aat ccgtg	gaact ggatt	ttagcc atatt	ggata tcatg	cttcc ggatg	tagac 180
gggtttc	aga tctgc	cagaa aatcc	gggaa aagtt	tttact tccct	gttat catgt	ctgaca 240
gcaaaag	tgg aggac	gggga taaa	atcat ggact	gtccg tggcg	gatga ttata	tattaca 300
aagccgt	ttta acccg	ctgga agtg	gttgc agagt	aaagg cgcag	ctgcg gcagt	acatg 360
cggtaca	agc agccc	agctt aaag	caggag gctga	atgca caga	aatac tatc	agaggg 420
atgaca	atca gcaag	agcag ccata	agtgt atcct	gtttg gaaag	gagat tcagt	tgacg 480
ccaacg	gagt ttctg	attct ttggt	atctg tgcga	gcgtc aggg	tacgg ttgtt	cttacg 540
gagga	attat ttgag	gcagt atggg	gtgaa cggtt	ttttt acag	caataa tact	gtgatg 600
gcgcata	tctg ggcgg	ctccg ggaga	aaaat aagga	accgt caaga	aatcc gaaat	ttata 660
aaaactg	tgtg gggga	gtggg atata	accatt gaaaa	atag 699		

<210> 35

<211> 1146

<212> DNA

<213> Enterococcus faecium

<400> 35

ttgaaaa	ata gaaata	aaaac cagtc	atgaa gatg	actatt tactt	tttaa aaac	agattg 60
tccgtta	aaaa tactg	cttat gatgg	tatat tccatt	cttga ttatt	gcggg tgttt	atctg 120
tttatct	ttaa aagata	atatt tgcaa	atgtc gtggt	tagcca tttta	gacag cttta	tctat 180
catgatc	ggg atgag	gcggg ggctg	tttat ctgga	aacct ttaag	gcgtc tgaga	tatgg 240
cttttct	tga tagc	ggttat gggcg	tggtt tttat	gatct tccgc	gtta tctgg	acagt 300
atttcaa	aat atttta	agga gatca	aaccgg gggat	cgata ctttg	gtgaa tgagg	atgcc 360
aacgat	attg ggctg	ccctc ggaag	ttggc tcgac	cgaaa gaaaa	atcaa ttcca	tacgg 420
catacc	tga cgaaa	cggaa aacgg	acgct gagc	ttgcag agcaa	aggaa aaac	gatctt 480
gtcatgt	atc tggcc	catga cctga	agacc ccgct	tccat cggtc	atagg atatt	ttgaac 540
ctgtta	aggg atgag	aatca gattt	ccgag gaact	taggg aaaa	tattt gtcca	tatca 600
ttggata	aagg ctgag	cgtct ggaag	aactg ataat	tgagt ttttt	gaaat tacga	ggttt 660
aatcttt	tcaa acatc	acgct tgtgt	acagc aaaat	tcaat tgac	gatgat gctgg	aaacag 720
ctgggg	tatg agttt	aaagg gatg	ctggc gggaa	aaaatc tgaa	atgtga atttg	atgtt 780
cagccag	aca tgatg	ctgtc ctgca	tatgag aata	cacca ttcgg	gtgaa agcca	ggcag 840
ctgagaa	atg ccgtc	agcta ctgct	atgag caaaa	atcata aacga	agggg atac	gattcc 900
accgaag	acc atgt	actcat caaaa	atcata aacga	agggg atac	gattcc tgggg	agagaa 960
ttggaa	agaa tcttt	gagca gtttt	taccgc ctgg	atgtat ctcga	agctc aagta	accggc 1020
ggggcc	gggtc tgggg	ccttgc cattg	caaaa gagat	tgttg aact	gcacca tggac	agatc 1080
actgccc	acaa gcgaa	aatgg tatca	caccag tttga	ggtta cattg	cccgt cgtag	gaaaa 1140
tcgtaa						1146

<210> 36

<211> 1071

<212> DNA

<213> Enterococcus faecium

-18-

<400> 36

atgatggaat	atcaaaacaa	taatggaaac	tatgacaaaa	ggaatcgtag	aaaagccaaa	60
aaaagaaaa	tgctttttta	cagggctgca	tgtgtcacac	tttgtttgct	cattgtttct	120
gtaatctttg	gagttgtgca	tttttttagg	gagagtaaag	atcccgccct	tttatccaaa	180
gaaaacacaa	aaacagacaa	gaactattcg	tggcttaccg	acgatcagaa	tgaggcagta	240
ccctcagttc	cagagccagc	catatccgac	caggctaaca	aaatttcggt	aaatatcaca	300
gcgccaaacg	ccattgtaat	gaataaagac	acaaatgagg	tattgtacca	gaaaaaaagc	360
acagccaaaa	ttgcgccggc	cagcactgct	aagatgatta	tggctttgac	agcacttgac	420
tattgttccc	cggaggatga	aatgaaagta	ggtgcggaga	ttggaatgat	tcaaagcgat	480
tcgtcaaccg	catggcttat	gaagggtgat	acactgactg	tcagacagct	cctgattgcc	540
cttatgcttc	cgtccggcaa	tgatgcagcc	tatacccttg	cagtcaatac	cggaaaggct	600
attgcagggtg	ataacagcct	gaccagtcag	caagcgattg	aagtattcat	ggataaggta	660
aatgaaaaag	ccgtggccct	tggcgccaca	aactcgaaat	ttgtagctcc	ggatggatat	720
gatgccgaag	ggcagtatac	tacagcttat	gaccttgcta	tcattgcaaa	agcatgtttg	780
gacaatccta	tcatttcgga	gattgtagcg	agttattcat	cctatgaaaa	atgggtcaaac	840
ggaagagagg	tcacttacia	caattccaat	gagcttctcg	atccgaacag	tccttattac	900
cgtccggagg	ttatcggttt	gaaaacagga	accagcagtc	ttggcgggcg	atgtattgtt	960
tctgcagcgg	tgatggacgg	agaaacctat	atctgtgtag	ttatgggttc	tacaaaggaa	1020
agcagggttc	aggacagcgt	tgatatttta	gataaaatca	aagcccagta	a	1071

<210> 37

<211> 969

<212> DNA

<213> Enterococcus faecium

<400> 37

atggagaaaa	taatagacat	aactgttttt	ggctgcgagc	caacgaaat	ggagggttttt	60
caaaagattt	cttatgagct	tgggtgttaca	gccacactca	taaaagattc	tatatcagaa	120
agcaatgctg	gattagctaa	tggatgccgg	tgtgtaagcg	taagccataa	agcggagcta	180
tcagaaccga	ttcttcttgc	gctaaaaaat	gcaggggtaa	aatatatcag	taccgggagc	240
attgggtttta	accatattga	tatacaggcg	gctgggttac	tgggtatggg	tgttggcaca	300
gtagaatact	cgccgggaag	tgtggccgat	tataccgtca	tgctgatgct	tatgctgatg	360
cgtggcacia	agtcgattct	gcgtgaaacc	cagaggcaga	attattgcct	gaatgacctg	420
gcgggaaaa	aactgcggga	tatgaccgtg	ggtgtgttag	gaactgggag	aatcggacag	480
gcagtcagtg	agcgcctgga	gggattcggt	tgtaaggat	tggcgtatga	ccgaaatcaa	540
aaagcaggag	cagactatgt	ttcgtttcat	gaactgctga	aaaaaagtga	cattgtttaca	600
ctgcatatcc	cgttggcgga	ggataccgcg	catatgattg	gctatgaaga	gctggaaatg	660
atgaaggaag	aggcgcttct	gatcaataca	ggcgggggcg	ctttagtggg	taccgcagca	720
ttggtagaag	cattaaaagg	acagaaaatc	ggcgggcgcc	tggatgtttt	ggaaggcgaa	780
gaaggtatct	tttaccatga	ctgcacccaa	agaagaatag	aacatccttt	cctgtcggtc	840
ctgcagggaa	tgccgaatgt	cattgtttacg	ccgcacacag	cctatcatat	ggaacgggtg	900
ttggttgaca	cggtcagaaa	tactattaga	aattgtttga	attttgaaag	gagtcctggga	960
aatgttttag						969

<210> 38

<211> 1032

<212> DNA

<213> Enterococcus faecium

<400> 38

atgttttagaa	ttaaagttgc	agttctgttt	gggggctgtt	cagaggaaca	taatgtttcg	60
ataaaatctg	cgatggagat	tgccgcaaac	atagatacaa	aaaaatatca	gccttattat	120
attggaatca	caaaatccgg	cgtttggaaa	atgtgtgaaa	aacctgtgtt	ggagtgggaa	180
caatatgcgg	gggatccggt	tgttttttcg	ccggacagaa	gtacgcatgg	tctgctgata	240
caaaaagaca	aagggtatga	aatccagcct	gtggatgtgg	tgtttccgat	gattcatggc	300
aagtttgggg	aggatggctc	catacaaggc	ttgcttgaat	tgtcaggcat	tccgtatgtg	360

-19-

ggatgcgata	ttcaaagctc	cgtgatctgc	atggataagg	cgcttgcata	taccgttggtg	420
aaaaatgctg	gtatcactgt	gcctgggttc	cggatccttc	aggaggggga	tcgcctggaa	480
acggaggatt	tcgtatatcc	cgtttttgta	aagcctgccc	gttccggctc	atcctttggc	540
gtaaacaagg	tatgcaaggc	agaagaactg	caggcagcaa	tcgaagaagc	aagaaaatat	600
gacagcaaga	ttttgattga	agaggccgtt	accgggagtg	aggtaggctg	cgccatactg	660
ggaaacggaa	atgatctcat	ggctggcgag	gtggatcaga	ttgagctgag	acacggcttt	720
tttaagattc	atcaggaagc	acagccggag	aagggatctg	aaaatgcagt	catccgagtt	780
ccagccgcct	taccggatga	ggtaagagaa	cagattcagg	aaacggcaat	gaagatttac	840
cggatacttg	gctgcagagg	attggcccgc	attgacctgt	ttttgcggga	ggacgggtgc	900
attgtgctga	atgaagtgaa	taccatgcca	ggttttactt	cctacagccg	ctatccccgc	960
atgatgacag	cagccggttt	tacgctttct	gaaatactgg	atcgcttgat	tgaactttca	1020
cttaggaggt	aa					1032

<210> 39

<211> 609

<212> DNA

<213> Enterococcus faecium

<400> 39

atgaaaaaga	actttgcctt	tttagatgaa	atgattcccc	ggatccgatg	ggatgccaaa	60
tatgccacct	gggacaattt	caccgggaaa	ccggtagacg	gatacatggt	aaaccgtggt	120
atgggaacga	aggagctggg	agttgctttg	cgtaaggctc	agaagatggc	ggagaagcta	180
ggatatgggt	tgctcttatg	ggacggctat	cgcccccagt	gcgcagtga	ttgttttctg	240
aattgggctt	cccaaccgga	agacaatctg	acgaaaaagc	gttactatcc	aaatatcaaa	300
aggaatgaga	tggttgcgaa	ggggtatgtg	gcctcacaat	ccagccacag	ccgtggaagt	360
acggttgacc	ttacaatttt	tcatttgaat	agcggtatgc	ttgttcctat	gggtggagat	420
tttgacttta	tggatgaacg	gtcacaccat	gccgcaagcg	gtctgagcga	agaagaatca	480
aaaaaccggc	agtgcttgcg	ttatatcatg	gagagtagcg	gatttgaagc	ctatcgttat	540
gaatggtggc	attacgtctt	ggcggacgag	ccatacccgg	atacatattt	tgatttttgc	600
attgcctag						609

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12803 A3

(51) International Patent Classification⁷: **C07K 14/315**,
C12N 15/11, 15/52

(21) International Application Number: PCT/US00/22086

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/149,313 17 August 1999 (17.08.1999) US

(71) Applicant (for all designated States except US): **BETH ISRAEL DEACONESS MEDICAL CENTER, INC.**
[US/US]; 1 Deaconess Road, Boston, MA 02215 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **INOUE, Roger, T.** [US/US]; 23 Roberts Road, Wellesley, MA 02481 (US). **TORRES-VIERA, Carlos** [VE/VE]; Calle Andrea de Ledesma, Qta La Torrera, Urb Sorocaima, Caracas, Venezuela (VE). **MOELLERING, Robert** [US/US]; 49

Longfellow Road, Wellesley Hills, MA 02481-5220 (US). **GOLD, Howard** [US/US]; Apartment 610, 135 Pleasant Street, Brookline, MA 02446-3489 (US). **ELIOPOULOS, George, M.** [US/US]; 5 Laurel Circle, Needham, MA 02494 (US).

(74) Agent: **PLUMER, Elizabeth, R.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:

— with international search report


(88) Date of publication of the international search report:
18 October 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/12803 A3

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*



(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a *vanR*-responsive promoter decoy.

INTERNATIONAL SEARCH REPORT

International Application No

PCT, JS 00/22086

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/315 C12N15/11 C12N15/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 07942 A (PASTEUR INSTITUT) 14 May 1992 (1992-05-14)	24-27,29
Y	the whole document, in particular pages 7, 46 and 51	1-6,8, 10-17,19
Y	--- WO 90 00624 A (BAYLOR COLLEGE MEDICINE) 25 January 1990 (1990-01-25) the whole document, in particular page 4 line 7 to page 5 line 25	1-17,19
A	--- PETER MITCHELL: "Facing up to antibiotic resistance" PHARMAPROJECTS MAGAZINE, vol. 3, no. 8, June 1998 (1998-06), pages 16-20, XP000943900 the whole document, in particular pages 18-19	1-23,28
	--- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 2001

Date of mailing of the international search report

18. 04. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Julia, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/22086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 12205 A (VIRUS RESEARCH INST INC ;BEATTIE DAVID T (US)) 26 March 1998 (1998-03-26) page 3 last paragraph to page 4 first paragraph ---	1-23,28
X	WO 96 08582 A (BERGERON MICHEL G ;OUELLETTE MARC (CA); ROY PAUL H (CA)) 21 March 1996 (1996-03-21) the whole document, in particular page 17, page 24 example 9, page 26 example 13 and Table 8 ---	24-26
P,X	DATABASE GALE GROUP NEWSLETTER DB [Online] D.J. DENOON: "Gene-Based strategy reverses vancomycin resistance" XP002154962 Database accession number 56646980 abstract & Gene Therapy Weekly 1999, Oct 18 ---	1-6, 10-23,28
Y	STEFAN EVERS AND PATRICE COURVALIN: "Regulation of VanB-type vancomycin resistance gene expression by the VanSB-VanRB two-component regulatory system in Enterococcus faecalis V583" JOURNAL OF BACTERIOLOGY, vol. 178, no. 5, March 1996 (1996-03), pages 1302-1309, XP002153486 US the whole document ---	1-5,7, 13-15
X	WO 94 14961 A (PASTEUR INSTITUT ;ARTHUR MICHEL (FR); DUTKA MALEN SYLVIE (FR); EVE) 7 July 1994 (1994-07-07) ---	24,25,27
Y	the whole document, in particular pages 6 and 8-10	1-5,7, 13-15
Y	F. NAVARRO AND P. COURVALIN: "Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens" ANTIMICROB AGENTS CHEMOTHER, vol. 38, no. 8, August 1994 (1994-08), pages 1788-1793, XP000984075 the whole document ---	1-5,8, 13-15

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCi, JS 00/22086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	B. CASADEWALL AND P. COURVALIN: "Characterization of the VanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339" JOURNAL OF BACTERIOLOGY, vol. 181, no. 12, June 1999 (1999-06), pages 3644-3648, XP002153485 US the whole document	1-5,9, 13-15
X	WO 99 01571 A (MODRUSAN ZORA D ;ID BIOMEDICAL CORP (CA)) 14 January 1999 (1999-01-14) thw whole document, in particular claim 4	24-27
X	M. ARTHUR ET AL., : "Regulated interactions between partner and non-partner sensors and response regulators that control glycopeptide resistance gene expression in enterococci" MICROBIOLOGY, vol. 145, no. PT8, August 1999 (1999-08), pages 1849-1858, XP000986365 the whole document, in particular paragraph bridging pages 1856-1857 and figure 2d	20,22
Y	GRISSOM-ARNOLD J ET AL: "INDUCTION OF VANA VANCOMYCIN RESISTANCE GENES IN ENTEROCOCCUS FAECALIS: USE OF A PROMOTER FUSION TO EVALUATE GLYCOPEPTIDE AND NONGLYCOPEPTIDE INDUCTION SIGNALS" MICROBIAL DRUG RESISTANCE, LIEBERT, US, vol. 3, no. 1, 1997, pages 53-64, XP000944092 ISSN: 1076-6294 the whole document, in particular page 61 righth column	20,22
Y	MOELLERING R C: "ANTIBIOTIC RESISTANCE: LESSONS FOR THE FUTURE" CLINICAL INFECTIOUS DISEASES, THE UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, US, vol. 27, no. SUPP. 01, August 1998 (1998-08), pages S135-S140, XP000943873 ISSN: 1058-4838 the whole document, in particular page S138 righth column last paragraph and page 139 righth column	20,22

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/22086

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ARTHUR M ET AL: "THE VANS-VANR TWO-COMPONENT REGULATORY SYSTEM CONTROLS SYNTHESIS OF DEPSIPEPTIDE PEPTIDOGLYCAN PRECURSORS IN ENTEROCOCCUS FAECIUM BM4147" JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 174, no. 8, April 1992 (1992-04), pages 2582-2591, XP000944110 ISSN: 0021-9193 cited in the application the whole document, in particular page 2587 left column and page 2588 left column second full-paragraph -----</p>	20, 22

INTERNATIONAL SEARCH REPORT

Int'l application No.
PCT/US 90/22086

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-23 as far as they comprise in vivo (therapeutic) methods, are directed to methods of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-5, 13-15, 24-27, 29 (partial) and 6, 10-12, 16-17, 19 (complete)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising introducing into the organism at least one anti-sense vancomycin resistance molecule under conditions to inhibit expression of a vancomycin resistance gene, wherein said vancomycin resistant organism is a vanA resistant organism and the anti-sense molecule is selected from the group consisting of a vanA antisense molecule, a vanR antisense molecule, a vanS antisense molecule, a vanH antisense molecule, a vanX antisense molecule, a vanY antisense molecule and a vanZ antisense molecule. Said method wherein the anti-sense vancomycin resistance molecule hybridizes to the complete vanA gene sequence or to a conserved region (from 10 to 30 nucleotides) thereof (encodes an active site of the ligase) or to the complete vanX gene sequence or to a conserved region thereof. Said method wherein introducing the anti-sense vancomycin resistance molecule comprises contacting the vancomycin resistant organism with at least one vector (enterococcal shuttle vector, bacteriophage, peptide nucleic acid molecule, enterococcal conjugative transposon or a pheromone-responsive plasmid) comprising one or more vanA "anti-sense vancomycin resistance molecules" under conditions to allow the vector to enter the organism and inhibit expression of one or more vancomycin resistance genes.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanA resistance/VanA gene cluster of SEQ ID No.: 1 (which includes vanR, SEQ ID No.: 18; vanS, SEQ ID No.: 19; vanH, SEQ ID No.: 20; vanA, SEQ ID No.: 21; vanX, SEQ ID No.: 22; vanY, SEQ ID No.: 23; vanZ, SEQ ID No.: 24 and conserved sequences thereof) SEQ ID No.: 5-10. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

2. Claims: 1-5, 13-15, 24-27, 29 (partial) and 7 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanB resistant organism and the anti-sense molecule is selected from the group consisting of a vanRB antisense molecule, a vanSB antisense molecule, a vanYB antisense molecule, a vanW antisense molecule, a vanHB antisense molecule and a vanXB antisense molecule.

An isolated nucleic acid that hybridizes under stringent

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

conditions to a nucleic acid molecule selected from the VanB resistance/VanB gene cluster of SEQ ID No.: 2 (which includes vanRB, SEQ ID No.: 26; vanSB, SEQ ID No.: 27; vanYB, SEQ ID No.: 28; vanHB, SEQ ID No.: 29; vanB, SEQ ID No.: 30; vanXB, SEQ ID No.: 31; vanW, SEQ ID No.: 32 and conserved sequences thereof) SEQ ID No.: 11-12. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

3. Claims: 1-5, 13-15, 24-27, 29 (partial) and 8 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanC resistant organism and the anti-sense molecule is selected from the group consisting of a vanC antisense molecule or vanC-2.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanC resistance (SEQ ID No.: 3) mediated by vanC-2 gene (SEQ ID No.: 33). A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

4. Claims: 1-5, 13-15, 24-27, 29 (partial) and 9 (complete)

Same method as invention group 1, but wherein said vancomycin resistant organism is a vanD resistant organism and the anti-sense molecule is selected from the group consisting of a vanD antisense molecule, a vanRD antisense molecule, a vanSD antisense molecule, a vanYD antisense molecule, a vanHD antisense molecule and a vanXD antisense molecule.

An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid molecule selected from the VanD resistance/VanD gene cluster of SEQ ID No.: 4 (which includes vanRD, SEQ ID No.: 34; vanSD, SEQ ID No.: 35; vanYD, SEQ ID No.: 36; vanHD, SEQ ID No.: 37; vanD, SEQ ID No.: 38; vanXD, SEQ ID No.: 39 and conserved sequences thereof) SEQ ID No.: 13. A vector comprising said isolated nucleic acid and an isolated vancomycin resistant organism comprising such a vector.

5. Claim : 20 and 22 (partial)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising enhancing expression of a vanH promoter in the organism, wherein the vanH promoter is not operatively coupled to a vancomycin resistance gene of the organism. Said method wherein the vanH promoter is contained on an enterococcus vector and enhancing expression comprises introducing into the organism

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

an amount of vector to express an amount of the vanH promoter sufficient to bind to phosphorylated VanR and thereby reduce vancomycin resistance in the organism.

6. Claims: 18, 21, 23, 28 (complete) and 20, 22 (partial)

a method for reducing vancomycin resistance in a vancomycin-resistant organism comprising enhancing expression of a vanH promoter in the organism to an amount sufficient to reduce vancomycin resistance in the organism, wherein the vanH promoter is operatively coupled to an antisense vancomycin resistance molecule (or if not operatively coupled then an antisense vancomycin resistance molecule operatively coupled to a vanH promoter is coadministered). Said method wherein the vanH promoter and the antisense vancomycin resistance molecule are contained on an enterococcus vector and enhancing expression comprises introducing into the organism an amount of vector to express an amount of the vanH promoter sufficient to bind to phosphorylated VanR and thereby reduce vancomycin resistance in the organism.

A method for reducing vancomycin resistance in a vancomycin-resistant organism comprising introducing into the organism a vector comprising a VanR-responsive promoter (vanH) operatively coupled to the vanA antisense molecule. A vector comprising a vanH promoter operatively coupled to an isolated nucleic acid molecule that hybridizes under stringent conditions to a nucleic acid molecule selected from the group consisting of SEQ ID No.: 1-13. An isolated vancomycin resistant organism comprising such a vector.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JS 00/22086

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9207942 A	14-05-1992	FR 2668489 A CA 2072350 A EP 0507934 A JP 5503222 T US 5871910 A US 6013508 A	30-04-1992 01-05-1992 14-10-1992 03-06-1993 16-02-1999 11-01-2000
WO 9000624 A	25-01-1990	AT 137806 T AU 4180889 A DE 68926455 D DE 68926455 T EP 0424473 A JP 3505672 T US 5294533 A	15-05-1996 05-02-1990 13-06-1996 31-10-1996 02-05-1991 12-12-1991 15-03-1994
WO 9812205 A	26-03-1998	AU 4485897 A	14-04-1998
WO 9608582 A	21-03-1996	AU 705198 B AU 3468195 A BR 9508918 A CA 2199144 A EP 0804616 A JP 10504973 T NO 9711111 A NZ 292494 A US 6001564 A	20-05-1999 29-03-1996 21-10-1997 21-03-1996 05-11-1997 19-05-1998 09-05-1997 25-03-1998 14-12-1999
WO 9414961 A	07-07-1994	FR 2699539 A FR 2699537 A CA 2152066 A EP 0672147 A JP 8505050 T US 6087106 A US 5770361 A	24-06-1994 24-06-1994 07-07-1994 20-09-1995 04-06-1996 11-07-2000 23-06-1998
WO 9901571 A	14-01-1999	AU 8327398 A EP 0996743 A	25-01-1999 03-05-2000

Form PCT/SA/210 (patent family annex) (July 1992)